Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2015	Sep. 14, 2015 Class A Common Stock [Member]	Sep. 14, 2015 Class B Common Stock [Member]
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q2
Trading Symbol	VTVT
Entity Registrant Name	vTv Therapeutics Inc.
Entity Central Index Key	0001641489
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		9,156,686	23,655,814

Condensed Combined Consolidated Balance Sheets (USD $)	Jun. 30, 2015	Dec. 31, 2014
Successor [Member]
Stockholder's Equity
Common stock, par value $0.01 per share, 1,000 shares authorized, 100 shares issued and outstanding	$ 1.00
Common stock receivable	(1.00)
Total stockholder's equity	0
TransTech Pharma LLC and High Point Pharmaceuticals LLC [Member]
Current assets:
Cash and cash equivalents	2,397,000	1,384,000
Restricted cash and cash equivalents	130,000	130,000
Prepaid expenses and other current assets	160,000	97,000
Total current assets	2,687,000	1,611,000
Note receivable	6,709,000	6,594,000
Property and equipment, net	3,516,000	3,778,000
Receivable due from a related party, net	800,000	800,000
Employee loans receivable - related party	57,000	58,000
Deferred offering costs	3,478,000
Other long-term assets	1,719,000	110,000
Total assets	18,966,000	12,951,000
Current liabilities:
Accounts payable and accrued expenses	7,913,000	3,079,000
Accounts payable and accrued expenses - related party	3,611,000	1,752,000
Deferred revenue	440,000
Short-term debt	2,189,000	155,000
Short-term debt - related party, net	46,586,000
Other liabilities	2,246,000	1,878,000
Total current liabilities	62,985,000	6,864,000
Debt - related party		27,310,000
Debt, net of current portion		2,110,000
Fair value of contingent distribution	27,054,000	26,359,000
Note payable	6,709,000	6,594,000
Other liabilities, net of current portion	3,163,000	4,434,000
Total liabilities	99,911,000	73,671,000
Commitments and contingencies
Redeemable convertible preferred units:
Redeemable convertible preferred units	513,163,000	438,086,000
Members' deficit:
Total members' deficit	(594,108,000)	(498,806,000)
Total liabilities, redeemable convertible preferred units, and members' deficit	18,966,000	12,951,000
TransTech Pharma, LLC (TTP) [Member]
Redeemable convertible preferred units:
Redeemable convertible preferred units	497,693,000
Members' deficit:
Members' deficit	(545,295,000)	(454,315,000)
Common member units	0	0
Total members' deficit	(545,295,000)	(454,315,000)
TransTech Pharma, LLC (TTP) [Member] \| Series A Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units:
Redeemable convertible preferred units	3,237,000	2,847,000
TransTech Pharma, LLC (TTP) [Member] \| Series B Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units:
Redeemable convertible preferred units	3,500,000	3,500,000
TransTech Pharma, LLC (TTP) [Member] \| Series C Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units:
Redeemable convertible preferred units	9,328,000	7,781,000
TransTech Pharma, LLC (TTP) [Member] \| Series D Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units:
Redeemable convertible preferred units	9,556,000	9,556,000
TransTech Pharma, LLC (TTP) [Member] \| Series E Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units:
Redeemable convertible preferred units	86,700,000	86,700,000
TransTech Pharma, LLC (TTP) [Member] \| Series F Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units:
Redeemable convertible preferred units	385,372,000	312,232,000
TransTech Pharma, LLC (TTP) [Member] \| Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units:
Redeemable convertible preferred units	497,693,000	422,616,000
High Point Pharmaceuticals, LLC (HPP) [Member]
Redeemable convertible preferred units:
Redeemable convertible preferred units	15,470,000
Members' deficit:
Members' deficit	(48,813,000)	(44,491,000)
Common member units	0	0
Total members' deficit	(48,813,000)	(44,491,000)
High Point Pharmaceuticals, LLC (HPP) [Member] \| Series A Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units:
Redeemable convertible preferred units	1,194,000	1,194,000
High Point Pharmaceuticals, LLC (HPP) [Member] \| Series B Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units:
Redeemable convertible preferred units	14,276,000	14,276,000
High Point Pharmaceuticals, LLC (HPP) [Member] \| Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units:
Redeemable convertible preferred units	$ 15,470,000	$ 15,470,000

Condensed Combined Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
Successor [Member]
Common stock par value	$ 0.01
Common Stock, Shares Authorized	1,000
Common Stock, Shares, Issued	100
Common Stock, Shares, Outstanding	100
TransTech Pharma, LLC (TTP) [Member]
Redeemable convertible preferred units, authorized	1,415,851,831
Redeemable convertible preferred units, issued	0
Redeemable convertible preferred units, outstanding	1,194,542,230
Redeemable convertible preferred units, aggregate liquidation preference	$ 222,410
Common member unit, par value
Common member unit, share authorized	1,512,722,844	1,512,722,844
Common member unit, share issued	4,188,607	4,188,607
Common member unit, share outstanding	4,188,607	4,188,607
TransTech Pharma, LLC (TTP) [Member] \| Series A Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units, par value	$ 0	$ 0
Redeemable convertible preferred units, authorized	8,571,337	8,571,337
Redeemable convertible preferred units, issued	8,571,337	8,571,337
Redeemable convertible preferred units, outstanding	8,571,337	8,571,337
Redeemable convertible preferred units, aggregate liquidation preference	2,545	2,545
TransTech Pharma, LLC (TTP) [Member] \| Series B Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units, par value	$ 0	$ 0
Redeemable convertible preferred units, authorized	2,547,593	2,547,593
Redeemable convertible preferred units, issued	2,547,593	2,547,593
Redeemable convertible preferred units, outstanding	2,547,593	2,547,593
Redeemable convertible preferred units, aggregate liquidation preference	3,500	3,500
TransTech Pharma, LLC (TTP) [Member] \| Series C Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units, par value	$ 0	$ 0
Redeemable convertible preferred units, authorized	2,343,922	2,343,922
Redeemable convertible preferred units, issued	2,243,922	2,243,922
Redeemable convertible preferred units, outstanding	2,243,922	2,243,922
Redeemable convertible preferred units, aggregate liquidation preference	5,514	5,514
TransTech Pharma, LLC (TTP) [Member] \| Series D Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units, par value	$ 0	$ 0
Redeemable convertible preferred units, authorized	2,442,361	2,442,361
Redeemable convertible preferred units, issued	2,442,361	2,442,361
Redeemable convertible preferred units, outstanding	2,442,361	2,442,361
Redeemable convertible preferred units, aggregate liquidation preference	9,556	9,556
TransTech Pharma, LLC (TTP) [Member] \| Series E Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units, par value	$ 0	$ 0
Redeemable convertible preferred units, authorized	32,789,595	32,789,595
Redeemable convertible preferred units, issued	32,789,595	32,789,595
Redeemable convertible preferred units, outstanding	32,789,595	32,789,595
Redeemable convertible preferred units, aggregate liquidation preference	86,700	86,700
TransTech Pharma, LLC (TTP) [Member] \| Series F Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units, par value	$ 0	$ 0
Redeemable convertible preferred units, authorized	1,367,157,023	1,367,157,023
Redeemable convertible preferred units, issued	1,145,947,422	1,145,947,422
Redeemable convertible preferred units, outstanding	1,145,947,422	1,145,947,422
Redeemable convertible preferred units, aggregate liquidation preference	114,595	114,595
High Point Pharmaceuticals, LLC (HPP) [Member]
Redeemable convertible preferred units, authorized	753,885,484
Redeemable convertible preferred units, issued	0
Redeemable convertible preferred units, outstanding	644,601,396
Redeemable convertible preferred units, aggregate liquidation preference	15,470
Common member unit, par value
Common member unit, share authorized	805,219,377	805,219,377
Common member unit, share issued	5,148,485	5,148,485
Common member unit, share outstanding	5,148,485	5,148,485
High Point Pharmaceuticals, LLC (HPP) [Member] \| Series A Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units, par value	$ 0	$ 0
Redeemable convertible preferred units, authorized	49,766,563	49,766,563
Redeemable convertible preferred units, issued	49,766,563	49,766,563
Redeemable convertible preferred units, outstanding	49,766,563	49,766,563
Redeemable convertible preferred units, aggregate liquidation preference	1,194	1,194
High Point Pharmaceuticals, LLC (HPP) [Member] \| Series B Redeemable Convertible Preferred Units [Member]
Redeemable convertible preferred units, par value	$ 0	$ 0
Redeemable convertible preferred units, authorized	704,118,921	704,118,921
Redeemable convertible preferred units, issued	594,834,833	594,834,833
Redeemable convertible preferred units, outstanding	594,834,833	594,834,833
Redeemable convertible preferred units, aggregate liquidation preference	$ 14,276	$ 14,276

Condensed Combined Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
TransTech Pharma LLC and High Point Pharmaceuticals LLC [Member]
Revenue	$ 110	$ 201	$ 160	$ 215
Operating expenses:
Research and development	5,146	4,030	12,531	8,172
Research and development - related party	556	505	947	767
General and administrative	2,297	2,858	4,292	7,985
Total operating expenses	7,999	7,393	17,770	16,924
Operating loss	(7,889)	(7,192)	(17,610)	(16,709)
Other income (loss), net	(1,510)	6	(850)	14
Other (expense) - related party	(168)	(157)	(336)	(344)
Interest (expense)	(45)	(42)	(90)	(76)
Interest (expense), net - related party	(800)	(14)	(1,339)	(5,392)
Investment (loss) - related party		(5)		(9)
Combined consolidated net loss	(10,412)	(7,404)	(20,225)	(22,516)
TransTech Pharma, LLC (TTP) [Member]
Operating expenses:
Combined consolidated net loss	(8,233)	(5,518)	(15,903)	(16,099)
Net loss per member unit:
Net loss attributable to member units, basic and diluted	(30,717)	(28,169)	(90,980)	(133,652)
Net loss per member unit, basic and diluted	$ (7.33)	$ (2.12)	$ (21.72)	$ (10.06)
Weighted-average number of common member units, basic and diluted	4,188,607	13,288,608	4,188,607	13,288,608
High Point Pharmaceuticals, LLC (HPP) [Member]
Revenue			160	0
Operating expenses:
Combined consolidated net loss	(2,179)	(1,886)	(4,322)	(6,417)
Net loss per member unit:
Net loss attributable to member units, basic and diluted	$ (2,179)	$ (1,886)	$ (4,322)	$ (10,143)
Net loss per member unit, basic and diluted	$ (0.42)	$ (0.10)	$ (0.84)	$ (0.52)
Weighted-average number of common member units, basic and diluted	5,148,485	19,609,698	5,148,485	19,609,698

Condensed Combined Consolidated Statements of Changes in Redeemable Convertible Units and Members Deficit (Unaudited) (USD $) In Thousands, except Share data	TransTech Pharma, LLC (TTP) [Member] USD ($)	High Point Pharmaceuticals, LLC (HPP) [Member] USD ($)	TransTech Pharma LLC and High Point Pharmaceuticals LLC [Member] USD ($)	Common Membership Units [Member] TransTech Pharma, LLC (TTP) [Member]	Common Membership Units [Member] High Point Pharmaceuticals, LLC (HPP) [Member]	HPP Members Deficit [Member] TransTech Pharma, LLC (TTP) [Member] USD ($)	HPP Members Deficit [Member] High Point Pharmaceuticals, LLC (HPP) [Member] USD ($)	Redeemable Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) [Member] USD ($)	Redeemable Convertible Preferred Units [Member] High Point Pharmaceuticals, LLC (HPP) [Member] USD ($)
Beginning balance, Redeemable convertible preferred units at Dec. 31, 2014			$ 438,086					$ 422,616	$ 15,470
Beginning balance value, Members' deficit at Dec. 31, 2014	(454,315)	(44,491)	(498,806)			(454,315)	(44,491)
Beginning balance units, Members' deficit at Dec. 31, 2014	4,188,607	5,148,485		4,188,607	5,148,485
Net loss	(15,903)	(4,322)	(20,225)			(15,903)	(4,322)
Change in redemption value of TTP redeemable convertible preferred units, value			(75,077)			(75,077)		75,077
Ending balance value, Members' deficit at Jun. 30, 2015	(545,295)	(48,813)	(594,108)			(545,295)	(48,813)
Ending balance, Redeemable convertible preferred units at Jun. 30, 2015	497,693	15,470	513,163					497,693	15,470
Ending balance units, Members' deficit at Jun. 30, 2015	4,188,607	5,148,485		4,188,607	5,148,485
Beginning balance, Redeemable convertible preferred units at Mar. 31, 2015
Net loss	(8,233)	(2,179)	(10,412)
Ending balance value, Members' deficit at Jun. 30, 2015	(545,295)	(48,813)	(594,108)
Ending balance, Redeemable convertible preferred units at Jun. 30, 2015	$ 497,693	$ 15,470	$ 513,163						$ 15,470
Ending balance units, Members' deficit at Jun. 30, 2015	4,188,607	5,148,485		4,188,607	5,148,485

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

Condensed Combined Consolidated Statements of Cash Flows (Unaudited) (TransTech Pharma LLC and High Point Pharmaceuticals LLC [Member], USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
TransTech Pharma LLC and High Point Pharmaceuticals LLC [Member]
Cash flows from operating activities
Net loss	$ (20,225)	$ (22,516)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	247	453
Change in fair value of contingent distribution	695
Amortization of debt discount - related party		4,773
Non-cash interest expense-distribution payable	27
Amortization of deferred financing costs		145
Impairment loss on carrying value of land	48
Bad debt expense - related party	230	230
Change in fair value of marketable securities - related party		10
Change in assets and liabilities
Accounts receivable		164
Prepaid expenses and other assets	(63)	(148)
Employee loans receivable - related party	1	(115)
Receivable due from a related party	(230)	(230)
Deferred offering costs	(1,110)
Other long-term assets	(1,609)	(4)
Accounts payable and accrued expenses	2,466	(2,134)
Accounts payable and accrued expenses - related party	1,859	1,024
Deferred revenue	440
Other liabilities	(930)	106
Net cash used in operating activities	(18,154)	(18,242)
Cash flows from investing activities
Purchases of property and equipment	(33)	(26)
Net cash used in investing activities	(33)	(26)
Cash flows from financing activities
Proceeds from debt issuance - related party	19,276	18,901
Repayment of debt	(76)	(73)
Net cash provided by financing activities	19,200	18,828
Net increase in cash and cash equivalents	1,013	560
Cash and equivalents, beginning of period	1,384	1,089
Cash and equivalents, end of period	2,397	1,649
Supplemental cash flow information
Cash paid for interest	62	75
Non-cash activities
Deferred offering costs included in accounts payable and accrued expenses	$ 2,368

Organization and Background (Successor [Member])

6 Months Ended

Jun. 30, 2015

Successor [Member]

Organization and Background

1.	Organization and Background

vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) is a holding company and was incorporated in the state of Delaware on April 2, 2015 for the sole purpose of becoming the managing member of vTv Therapeutics LLC (“vTv LLC”). As described in more detail in Note 12 of the Condensed Combined Consolidated Financial Statements of TransTech Pharma, LLC (“TTP”) and High Point Pharmaceuticals, LLC (“HPP”), the Company completed an initial public offering (the “IPO”) on August 4, 2015 of 7,812,500 shares of its Class A common stock at a price of $15.00 per share. The IPO raised net proceeds of approximately $109.0 million after underwriting discounts and commissions but before expenses. The Company used the net proceeds of the IPO to acquire nonvoting common units (“vTv Units”) of vTv LLC, an entity created to hold substantially all of the assets and operations of TTP and HPP, which assets and operations were transferred to such entity in a series of pre-IPO reorganization transactions (the “Reorganization Transactions”). vTv LLC is an entity under common control with vTv Therapeutics Inc.

Subsequent to the IPO and the Reorganization Transactions, vTv Therapeutics Inc. is a holding company and its principal asset is a controlling equity interest in vTv LLC, the successor company to TTP and HPP. The Company is the sole managing member of vTv LLC, and although it holds a minority economic interest in vTv LLC, the Company has the sole voting power to operate and control all of the business and affairs of vTv LLC. As a result, beginning in the third quarter of 2015, vTv Therapeutics Inc. will consolidate vTv LLC’s financial results using the variable-interest entity model (because the Company has determined that vTv LLC is a variable-interest entity and that the Registrant is the primary beneficiary of vTv LLC) and report a noncontrolling interest related to the portion of vTv Units not owned by us.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References+ Details

Description of Business and Basis of Presentation

6 Months Ended

Jun. 30, 2015

Description of Business and Basis of Presentation

1.	Description of Business and Basis of Presentation

TransTech Pharma, Inc. (“TTP Inc.”) was incorporated in the State of Delaware on December 3, 1998. TTP Inc., was formed to develop and apply proprietary high-throughput medicinal chemistry approaches as its platform technology to yield clinical drug candidates in a timely and cost effective manner.

In November 2013, TTP Inc. underwent a reorganization by contributing all of its assets to TransTech Pharma, LLC (“TTP,” or “TransTech”), a Delaware limited liability company, in exchange for (a) assumption of all liabilities of TTP Inc. and (b) all membership units of the Company. The membership units of the Company were then distributed to the shareholders of TTP Inc. to match in kind and number the shares held by them in TTP Inc.

On March 12, 2008, TTP Inc. formed High Point Pharmaceuticals, LLC (“HPP”) and transferred various intellectual property (principally consisting of certain programs) to HPP in exchange for common and preferred units as well as warrants to purchase an additional 6.7 million common units. TTP Inc. subsequently distributed these equity investments to its unit holders on a pro-rata basis, based on the unit holders’ ownership in TTP Inc. HPP is primarily responsible for all preclinical and clinical development efforts, as well as maintenance of the intellectual property portfolio for all of its drug candidate programs. TTP provides research employees and facilities, for which TTP charges HPP a maintenance fee. TTP has no further obligation beyond the items described above, and TTP has no obligation to the creditors of HPP as a result of its involvement with HPP. For the six months ended June 30, 2015 and 2014, HPP had revenues of $160 and $0, respectively. For the six months ended June 30, 2015 and 2014, HPP had a net loss of $4.3 million and $6.4 million, respectively.

TTP and HPP are collectively referred to as “the Company.”

The condensed combined consolidated financial statements include the consolidated accounts of TTP, its wholly owned subsidiary (prior to December 31, 2014), High Point Clinical Trials Center, LLC (“HPCTC”), and the combined accounts of HPP. All significant intercompany balances and transactions have been eliminated. Condensed combined financial statements are presented as these entities are under common ownership and management.

Reorganization and Initial Public Offering (IPO)

During July 2015, TTP and HPP were renamed vTvx Holdings I and vTvx Holdings II, respectively. The Company then entered into a series of Reorganization Transactions (as described in Note 12) through which the operations of vTvx Holdings I and vTvx Holdings II were combined into vTv LLC. As a result of the Reorganization Transactions, substantially all of the assets of TTP and HPP were transferred to vTv LLC, an entity controlled by vTv Therapeutics Inc.

On August 4, 2015, vTv Therapeutics Inc. consummated its IPO of 7,812,500 shares of its Class A common stock at a price of $15.00 per share. The IPO raised net proceeds of approximately $109.0 million after underwriting discounts and commissions but before expenses. vTv Therapeutics Inc. used the net proceeds of the IPO to acquire vTv Units from vTv LLC, an entity under common control with vTv Therapeutics Inc. and the holder of substantially all of the assets of the Company. Following the reorganization transactions, vTv Therapeutics Inc. intends to use the net proceeds of the offering to fund clinical development, studies, and trials for its various products and other drug candidates, for working capital and other general corporate purposes.

Successor [Member]

Description of Business and Basis of Presentation

2.	Basis of Presentation

The Company’s balance sheet has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Separate statements of operations, cash flows, and changes in stockholder’s equity and comprehensive income have not been presented because the Company has had no operations from its inception (April 2, 2015) through June 30, 2015.

Redeemable Convertible Preferred Units and Warrants

6 Months Ended

Jun. 30, 2015

Redeemable Convertible Preferred Units and Warrants

7.	Redeemable Convertible Preferred Units and Warrants

Authorized, Issued, and Outstanding Redeemable Convertible Preferred Units

As of June 30, 2015, TTP was authorized to issue 1,415,851,831 preferred units in the aggregate. The following table summarizes authorized, issued and outstanding redeemable convertible preferred units as of June 30, 2015. The preferred units are carried at the greater of the original cost, liquidation preference, or fair value as indicated in the table below (in thousands except per-member unit data):


	Member Units
	Authorized		Outstanding		Original Cost		Liquidation Preference		Fair Value		Carrying Value
Series A Preferred		8,571,337		8,571,337	$	2,545	$	2,545	$	3,237	$	3,237
Series B Preferred		2,547,593		2,547,593		3,500		3,500		2,897		3,500
Series C Preferred		2,343,922		2,243,922		5,514		5,514		9,328		9,328
Series D Preferred		2,442,361		2,442,361		9,556		9,556		7,707		9,556
Series E Preferred		32,789,595		32,789,595		86,700		86,700		69,923		86,700
Series F Preferred		1,367,157,023		1,145,947,422		64,476		114,595		385,372		385,372

Total		1,415,851,831		1,194,542,230	$	172,291	$	222,410	$	478,464	$	497,693

No TTP redeemable convertible units were issued or repurchased during the six months ended June 30, 2015.

As of June 30, 2015, HPP was authorized to issue 753,885,484 preferred units in the aggregate. The following table summarizes authorized, issued and outstanding redeemable convertible preferred units as of June 30, 2015. The preferred units are carried at the greater of the original cost, liquidation preference, or fair value as indicated in the table below (in thousands except per member unit data):


	Member Units
	Authorized		Outstanding		Original Cost		Liquidation Preference		Fair Value		Carrying Value
Series A Preferred		49,766,563		49,766,563	$	1,194	$	1,194	$	—	$	1,194
Series B Preferred		704,118,921		594,834,833		14,276		14,276		—		14,276

Total		753,885,484		644,601,396	$	15,470	$	15,470	$	—	$	15,470

There were no HPP redeemable convertible preferred units issued or repurchased during the six months ended June 30, 2015.

Conversion Rights

Each TTP Series A, Series B, Series C, Series D, Series E and Series F preferred unit (collectively, the “TTP Series Preferred”) is convertible, at the option of the holder, into common units of TTP based on the total consideration received by TTP for each series of the preferred units (plus declared and unpaid distributions) divided by the conversion price. Initially the conversion prices were $0.296973, $1.37385, $2.457293, $3.91268996, $2.64413153 and $0.10 per common unit for the Series A, Series B, Series C, Series D, Series E and Series F preferred units, respectively. The conversion prices are subject to adjustments for stock splits, stock dividends, combinations or any other similar event.

Subsequently, the Series C conversion price was adjusted to $0.203979 per common unit and the Series D conversion price was adjusted to $2.644131 per common unit. The foregoing conversion prices were in effect at June 30, 2015.

Each HPP Series A and B preferred unit is convertible, at the option of the holder, into HPP common units based on the total consideration received by HPP for each series of the preferred units (plus declared and unpaid distributions) divided by the conversion price. Initially the conversion prices were $0.024 and $0.024 per common unit for the Series A and Series B preferred units, respectively.

Each series of preferred units also contains a provision whereby the units shall automatically convert into common units based on the then-effective conversion price upon the occurrence of the closing of a qualified public offering pursuant to an effective registration statement under the Securities Act of 1933. See Note 12, “Subsequent Events.”

Rights to Distributions Prior to Termination of the Company

Holders of preferred units are entitled to receive distributions of cash or other property prior to termination of the Company when and if declared by the Board of Directors. Such distributions are made to members of the Company on a pro rata basis (and with respect to preferred units, on an as-converted basis). Holders of preferred units are entitled to share in any distribution made to the common units.

Voting Rights

Each holder of TTP and HPP Series Preferred Units is entitled to vote on all matters on which the holders of common units are entitled to vote, based on the number of common units into which their TTP and HPP Series Preferred units are convertible. In addition, holders of preferred units are entitled to a separate class vote on certain extraordinary matters.

Liquidation

Liquidation is deemed to occur in the event of any liquidation, dissolution or winding up of TTP, whether voluntary or involuntary, as well as (if determined by the Board) any change of control of the Company that includes (i) an acquisition of the Company in which the unit holders of the Company immediately prior to such transaction do not own a majority of the outstanding voting securities of the acquiring entity immediately following such transaction and (ii) a sale of all or substantially all of the assets of the Company.

In the event of any liquidation, dissolution or winding up of TTP, the holders of the TTP Series F units are entitled to receive, prior to the distribution to the other holders, a liquidation amount equal to the TTP Series F consideration paid per unit ($0.10) plus all declared but unpaid distributions thereon. Thereafter, the holders of all other series of TTP Series Preferred are entitled to receive, prior to distribution to the holders of common units, a liquidation amount equal to the consideration paid per unit ($0.296973, $1.37385, $2.457293, $3.91268996, $2.64413153, $.024 and $.024 for the TTP Series A, TTP Series B, TTP Series C, TTP Series D, TTP Series E, HPP Series A and HPP Series B units, respectively), plus all declared but unpaid distributions thereon.

Redemption

On May 18, 2015, the Board of Directors amended the TTP operating agreements and revised the redemption dates of the Company’s redeemable convertible units as follows:

Beginning January 1, 2020, the holders of a majority of the outstanding TTP Series F preferred units may demand that TTP redeem up to all of the outstanding TTP Series F preferred units. Beginning January 8, 2020, the holders of a majority of the outstanding TTP Series A preferred units and/or a majority of the outstanding TTP Series B preferred units and/or a majority of the outstanding TTP Series C preferred units may demand that TTP redeem up to all of the outstanding units of each respective series of preferred units. Beginning on November 26, 2020, the holders of a majority of the outstanding shares of TTP Series E preferred units may demand that TTP redeem up to all of the outstanding units of such series of preferred units. Beginning on May 20, 2020, the holders of a majority of the outstanding shares of TTP Series D preferred units may demand that TTP redeem up to all of the outstanding units of such series. The redemption price per unit for each such series continues to be the greater of (a) such series’ liquidation value (i.e., the original cost for each unit of such series (as adjusted for any unit split, unit dividend or other similar events) plus all declared and unpaid distributions on such series and (b) such series’ fair market value (plus all declared but unpaid distributions on such series).

The redemptions of TTP Series Preferred can only be made out of funds legally available for that purpose (which determination would require the TTP board of directors to consider whether, following such redemption, TTP would be able to continue as a going concern). If TTP has insufficient funds legally available to redeem all TTP Series Preferred required to be redeemed on the mandatory redemption date, those funds legally available for such purpose shall be first used to ratably redeem the maximum number of any Series F preferred units that have properly demanded that TTP redeem such units in accordance with the TTP operating agreement before the units of any other series of TTP Series Preferred are redeemed. As of June 30, 2015 there were no funds legally available for redemption.

On May 18, 2015, the Board of Directors amended the HPP operating agreements and revised the redemption dates of the Company’s redeemable convertible units as follows:

Beginning January 1, 2020, the holders of a majority of the outstanding HPP Series B preferred units may demand that HPP redeem up to all of the outstanding units of such series. Beginning April 11, 2020, the holders of a majority of the outstanding HPP Series A preferred units may demand that HPP redeem up to all of the outstanding units of such series. The redemption price per unit for each such series continues to be the greater of (a) such series’ liquidation value (i.e., the invested amount for each unit of such series (as adjusted for any unit split, unit dividend or similar events)) and (b) such series’ fair market value.

The redemptions of HPP preferred units can only be redeemed out of funds legally available for that purpose (which determination would require the HPP board of directors to consider whether, following such redemption, TTP would be able to continue as a going concern). If HPP has insufficient funds legally available to redeem all of the HPP Series A and Series B units required to be redeemed on the mandatory redemption date, those funds legally available for such purpose shall be first used to ratably redeem the maximum number of any HPP Series B preferred units that have properly requested that HPP redeem such units in accordance with the HPP operating agreement before the HPP Series A preferred units are redeemed. As of June 30, 2015, no funds were legally available for redemption.

Registration Rights Agreement

Preferred unit holders have certain preferential rights in connection with public offerings and sales of common units.

Common Member Units

Authorized, Issued, and Outstanding Common Membership Units

TTP’s common units consist of one class, with no par value, 1,512,722,844 units authorized, and 4,188,607 units issued and outstanding at June 30, 2015 and December 31, 2014, respectively. At June 30, 2015, the Company had reserved common membership units for future issuance as follows:


	TTP Common Units Reserved
Conversion of TTP Series A Preferred		8,571,337
Conversion of TTP Series B Preferred		2,547,593
Conversion of TTP Series C Preferred		27,032,037
Conversion of TTP Series D Preferred		3,614,117
Conversion of TTP Series E Preferred		32,789,595
Conversion of TTP Series F Preferred		1,145,947,422
Outstanding TTP warrants on common units		977,462

Total common units reserved for future issuance		1,221,479,563

HPP’s common units consist of one class, with no par value, 805,219,377 units authorized, and 5,148,485 units issued and outstanding at June 30, 2015 and December 31, 2014, respectively. At June 30, 2015, the Company had reserved common membership units for future issuance as follows:


	HPP Common Units Reserved
Conversion of HPP Series A Preferred		49,766,563
Conversion of HPP Series B Preferred		594,834,833
Outstanding HPP warrants on common units		903,712
Options for HPP common units		505,837

Total HPP common shares reserved for future issuance		646,010,945

As of June 30, 2015, HPP had 505,837 options outstanding with a strike price of $0.024 expiring at various dates in 2018. As of June 30, 2015 the fair value of the options was $0.

Liquidation Rights

In the event of any liquidation or dissolution of the Company, the holders of the TTP Series G Units are entitled to receive the Series G liquidation preference prior to the distribution to the other holders. See Note 12, “Subsequent Events—TTP Series G” for additional details regarding the TTP Series G Units. The holders of the common units are entitled to share ratably with holders of the TTP and HPP Series Preferred, on an as-if-converted-to-common-units basis, in the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for all other Preferred Series shares.

Distributions Prior to Termination of the Company and Voting Rights

The holders of the common units are entitled to receive distributions of cash or other property prior to termination of the Company when and if declared by the Board of Directors. Such distributions would be made to members of the Company on a pro-rata basis.

The holders of the common units have the right to one vote per unit.

Warrants on Common Units

TTP’s outstanding warrants and related exercise prices for the six months ended June 30, 2015 are as follows:


	Warrants			Weighted- Average Exercise Price Per Unit
Outstanding balance at January 1, 2015		991,337		$	2.94
Cancelled		(13,875	)		2.64

Outstanding balance at June 30, 2015		977,462		$	2.95

The following table summarizes information related to the outstanding TTP warrants as of June 30, 2015:


Exercise Price		Expiration Date	Warrants Outstanding		Warrants Exercisable
$	2.64	1/1/2016		25,000		25,000
$	2.64	11/22/2016		90,000		90,000
$	2.64	12/31/2016		24,962		24,962
$	3.00	8/27/2017		30,000		30,000
$	3.00	12/17/2017		800,000		800,000
$	3.00	1/1/2018		7,500		7,500

				977,462		977,462

HPP’s outstanding warrants and related exercise prices for the six months ending June 30, 2015 are as follows:


	Warrants			Weighted- Average Exercise Price Per Unit
Outstanding balance at January 1, 2015		917,587		$	0.02
Cancelled		(13,875	)		0.02

Outstanding balance at June 30, 2015		903,712		$	0.02

The following table summarizes information about the outstanding HPP warrants as of June 30, 2015:


Exercise Price		Expiration Date	Warrants Outstanding		Warrants Exercisable
$	0.02	1/1/2016		25,000		25,000
$	0.02	11/22/2016		26,250		26,250
$	0.02	12/31/2016		24,962		24,962
$	0.02	12/17/2017		800,000		800,000
$	0.02	4/11/2018		15,000		15,000
$	0.02	5/15/2019		12,500		12,500

				903,712		903,712

Successor [Member]

Redeemable Convertible Preferred Units and Warrants

3.	Stockholder’s Equity

The Company has authorized for issuance 1,000 shares of common stock with a par value of $0.01 per share (the “Common Stock”). Under a Subscription Agreement dated April 15, 2015, MacAndrews & Forbes Incorporated (“MacAndrews”) agreed to fund $1.00 to the Company in exchange for 100 shares of Common Stock, which are reflected on the Company’s balance sheet as issued and outstanding. The Common Stock receivable from MacAndrews is reflected as a reduction to stockholder’s equity on the Company’s balance sheet.

Holders of Common Stock are entitled to (i) one vote for each share held of record on all matters submitted to a vote of stockholders and (ii) receive dividends, when and if declared by the board of directors out of funds legally available therefor, subject to any statutory or contractual restrictions on the payment of dividends.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

+ Details

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2.	Summary of Significant Accounting Policies

Unaudited Interim Financial Information

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying balance sheet as of June 30, 2015, statements of operations for the three and six months ended June 30, 2015 and 2014 and cash flows for the six months ended June 30, 2015 and 2014 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2014 contained in the final prospectus filed by the Company with the SEC on July 31, 2015 relating to the IPO. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of June 30, 2015 and the results of operations for the three and six months ended June 30, 2015 and 2014 and cash flows for the six months ended June 30, 2015 and 2014. The December 31, 2014 balance sheet included herein was derived from the audited financial statements, but does not include all disclosures or notes required by GAAP for complete financial statements.

The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2015 and 2014 are unaudited. Interim results are not necessarily indicative of results for an entire year.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

On an ongoing basis, the Company evaluates its estimates, including those related to the useful lives of property and equipment, the fair value of the Company’s membership units, the fair value of redeemable preferred units, the fair value of derivative liabilities, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.

Concentration of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits.

The accounts receivable balance at June 30, 2015 was $0.

One customer represented 100% of the revenue earned during the six months ended June 30, 2015. Two customers represented 100% of the revenue during the six months ended June 30, 2014.

Cash and Cash Equivalents

The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Restricted Cash and Cash Equivalents

Restricted cash and cash equivalents reflect cash and cash equivalents that are pledged as collateral required by the terms of operating leases on facilities used by HPCTC.

Accounts Receivable

On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables.

Property and Equipment and other Long-lived Assets

The Company periodically assesses it property and equipment and other long-lived assets for impairment in accordance with the relevant accounting guidance. During 2014, the Company determined that certain of its land assets met the criteria for held-for-sale accounting treatment and, accordingly, adjusted the carrying value of such assets to the amount of the expected proceeds less costs of disposal, which was lower than the original carrying value. As of June 30, 2015 and December 31, 2014, the carrying value of assets held for sale was $2.7 million and $2.8 million, respectively.

Revenue Recognition

The Company uses the revenue recognition guidance established by ASC Topic 605, “Revenue Recognition.” The Company recognizes revenue when 1) persuasive evidence of an arrangement exists; 2) the service has been provided to the customer; 3) collection of the fee is reasonably assured; and 4) the amount of the fee to be paid by the customer is fixed or determinable. In determining the accounting for collaboration and alliance agreements, the Company follows the provisions of ASC Topic 605, Subtopic 25, “Multiple-Element Arrangements” (“ASC 605-25”) and ASC 808 (“Collaborative Arrangements”). ASC 605-25 provides guidance on whether an arrangement that involves multiple revenue-generating activities or deliverables should be divided into separate units of accounting for revenue recognition purposes and, if division is required, how the arrangement consideration should be allocated among the separate units of accounting. If a deliverable has value on a stand-alone basis, the Company treats the deliverable as a separate unit of accounting. If the arrangement constitutes separate units of accounting according to the separation criteria of ASC 605-25, the consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria is applied to each unit. The Company determines how to allocate amounts received under agreements among the separate units based on the respective selling price of each unit. If the arrangement constitutes a single unit of accounting, the revenue recognition policy must be determined for the entire arrangement and the consideration received is recognized over the period of inception through the date the last deliverable within the single unit of accounting is expected to be delivered.

Collaboration research and development revenue is earned and recognized as research is performed and related expenses are incurred. Non-refundable upfront fees are recorded as deferred revenue and recognized into revenue as license fees and milestones from collaborations on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, it recognizes non-refundable upfront fees into revenue ratably over the period during which the product deliverable is provided to the customer.

Revenue for non-refundable payments based on the achievement of milestone events under collaborative arrangements is recognized in accordance with ASC Topic 605, Subtopic 28, “Milestone Method” (“ASC 605-28”). Milestone events under the Company’s collaboration agreements may include research, development, regulatory, commercialization, and sales events. Under ASC 605-28, a milestone payment is recognized as revenue when the applicable event is achieved if the event meets the definition of a milestone and the milestone is determined to be substantive. ASC 605-28 defines a milestone event as an event having all of the following characteristics: (1) substantive uncertainty regarding achievement of the milestone event exists at the inception of the arrangement; (2) the event can only be achieved based, in whole or in part, on either the Company’s performance or a specific outcome resulting from the Company’s performance; and (3) if achieved, the event will result in additional payment due to the Company. The Company also treats events that can only be achieved based, in whole or in part, on either a third party’s performance or a specific outcome resulting from a third party’s performance as milestone events if the criteria of ASC 605-28 are otherwise satisfied.

Research and development costs that are reimbursable under collaboration agreements are recorded in accordance with ASC Topic 605, Subtopic 45, “Principal-Agent Considerations.” Amounts reimbursed under a cost-sharing arrangement are reflected as reductions of research and development expense.

Income Taxes

The Company is treated as a partnership for income tax purposes. Accordingly, the allocated share of taxable income or loss is includable in the income tax returns of the Company’s members. The Company recognizes the effect of income tax positions only if these positions are more likely than not of being sustained. Changes in recognition or measurement are reflected in the period in which each change occurs. The Company has not recognized any uncertain tax positions and no examinations are currently being conducted by U.S., state, or local taxing authorities.

Deferred Offering Costs

Legal and accounting costs of $3.5 million, which were incurred in connection with the IPO, are reflected on the balance sheet as of June 30, 2015 as capitalized deferred offering costs. Following the consummation of the IPO (see Note 12 for more information), deferred offering costs will be offset against the proceeds of the offering and included in members’ deficit.

Segment and Geographic Information

Operating segments are defined as an enterprise’s components (business activities from which it earns revenue and incurs expenses) for which discrete financial information is (1) available; and (2) is regularly reviewed by the chief operating decision maker (CODM) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its President and Chief Executive Officer. The Company’s business operates in one reportable segment comprised of one operating segment.

Recently Issued Accounting Pronouncements Not Yet Adopted

In April 2015, the FASB issued ASU No. 2015-04, “Compensation—Retirement Benefits (Topic 715): Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets,” (“ASU 2015-04”). For an entity with a fiscal year-end that does not coincide with a month-end, the amendments in this update provide a practical expedient that permits the entity to measure defined benefit plan assets and obligations using the month-end that is closest to the entity’s fiscal year-end and apply that practical expedient consistently from year to year. The practical expedient should be applied consistently to all plans if an entity has more than one plan. This ASU is effective for fiscal years beginning after December 15, 2015, with early adoption permitted. The Company does not expect ASU 2015-04 to have a material impact on its combined consolidated financial statements upon adoption.

In April 2015, the FASB issued ASU No. 2015-05, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement,” (“ASU 2015-05”). The amendments in this update provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This ASU is effective for fiscal years beginning after December 15, 2015, with early adoption permitted. The Company does not expect ASU 2015-05 to have a material impact on its combined consolidated financial statements upon adoption.

In April 2015, the FASB issued ASU No. 2015-06, “Earnings Per Share (Topic 260): Effects on Historical Earnings per Unit of Master Limited Partnership Dropdown Transactions (a consensus of the Emerging Issues Task Force),” (“ASU 2015-06”). The amendments in this update specify that for purposes of calculating historical earnings per unit under the two-class method, the earnings (losses) of a transferred business before the date of a dropdown transaction should be allocated entirely to the general partner. In that circumstance, the previously reported earnings per unit of the limited partners (which is typically the earnings per unit measure presented in the financial statements) would not change as a result of the dropdown transaction. Qualitative disclosures about how the rights to the earnings (losses) differ before and after the dropdown transaction occurs for purposes of computing earnings per unit under the two-class method also are required. This ASU is effective for fiscal years beginning after December 15, 2015, with early adoption permitted. The amendments in this update should be applied retrospectively for all financial statements presented. The Company does not expect ASU 2015-06 to have a material impact on its combined consolidated financial statements upon adoption.

In June 2015, the FASB issued ASU No. 2015-10, “Technical Corrections and Improvements,” (“ASU 2015-10”). The amendments in this update represent changes to clarify the Codification, correct unintended application of guidance, or make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The effective dates of transition guidance varies based on the amendments in this update. The amendments in this update that require transition guidance are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. All other amendments will be effective upon the issuance of this update. The Company does not expect ASU 2015-10 to have a material impact on its combined consolidated financial statements upon adoption.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

Repurchase of Former Officer's Interest

6 Months Ended

Jun. 30, 2015

Postemployment Benefits [Abstract]

Repurchase of Former Officer's Interest

3.	Repurchase of Former Officer’s Interest

On March 28, 2014, the Company entered into a reaffirmation and pledge agreement (“Pledge Agreement”) with a former officer and director (“the Former Officer”) and certain entities related to the officer (collectively with the Former Officer, the “Former Officer and Related Entities”) of the Company. Pursuant to the Pledge Agreement, the Former Officer granted a security interest to the Company in 18,730,276 Series F convertible preferred units of TTP and 9,363,128 Series B convertible preferred units of HPP owned by the Former Officer (the “Pledged Units”) to secure the Former Officer’s obligations to the Company under a promissory note (the “2007 Note”) issued by the Former Officer to the Company. See further discussion of the 2007 Note in Note 4.

On December 30, 2014, the Company’s board of directors authorized a repurchase of units from the Former Officer and Related Entities. The terms of the unit repurchase are stipulated in a Letter Agreement (the “Former Office Agreement”) with the Former Officer and Related Entities. The Former Officer Agreement superseded all prior understandings with respect to any sales or other similar transactions relating to the Company, stipulating that the Company would repurchase all of the Company’s issued and outstanding units owned by the Former Officer and Related Entities, including any warrants and options to purchase common units. These included 9,100,001 common units of TTP, 14,462,213 common units of HPP, 108,781,071 Series B convertible preferred units of HPP, 218,818,574 Series F convertible preferred units of TTP, 2,776,522 warrants for common units of TTP, 750,000 warrants for common units of HPP and 58,750 options for common units of HPP (collectively, the “Repurchased Units”). All units repurchased by the Company were legally retired and resumed the status of authorized and unissued common and preferred units.

In exchange for the Repurchased Units, under the Former Officer Agreement, the Company agreed to make periodic cash payments to the Former Officer and Related Entities totaling $7.5 million between December 30, 2014 and September 30, 2017. Payments consist of $2.5 million paid at closing of the agreement on December 30, 2014 and $5.0 million to be paid in eight equal quarterly installments beginning December 31, 2015. This obligation is recorded in other liabilities in the combined consolidated balance sheet. The Company also transferred 100% of its ownership interests in HPCTC to the Former Officer and agreed to make future distributions to the Former Officer (the “Contingent Distributions”). The distributions payable amounts are to be made in the form of cash or certain securities upon the occurrence of certain operational or transactional events and milestones. The Contingent Distributions are reported at fair value on the combined consolidated balance sheet and classified as Fair value of contingent distribution as of June 30, 2015 and December 31, 2014. The maximum Contingent Distributions in aggregate equal $150 million. However, the Company’s obligation to pay the Contingent Distributions expires upon the occurrence of any one of a number of specified termination events. In addition, the Company exchanged the Pledged Units for TTP Perpetual Securities in the principal amount of approximately $6.0 million and HPP Perpetual Securities in the principal amount of approximately $0.5 million (the “Perpetual Securities”). All Pledged Units exchanged by the Company were legally retired and resumed the status of authorized and unissued preferred units. The Perpetual Securities remain subject to the Pledge Agreement, have no fixed maturity date and accrue interest at a rate per annum equal to the 2007 Note. The Perpetual Securities may be prepaid without penalty in whole or in part at any time. Prepayments shall first be applied to accrued interest and then to principal. The Perpetual Securities obligation is presented as a note payable on the Condensed Combined Balance Sheet as of June 30, 2015 and December 31, 2014.

In conjunction with the issuance of the Perpetual Securities, the Company gave the Former Officer an irrevocable right to sell back to the Company all of the Perpetual Securities. This right is exercisable at the discretion of the Former Officer. The exercise price of the put feature for all of the Perpetual Securities is the amount then outstanding on the 2007 Note. The Former Officer also gave the Company an irrevocable right to repurchase all of the Perpetual Securities. This right is exercisable at the earlier to occur of: (1) the maturity of the 2007 Note or (2) the date the Former Officer receives distribution payable payments under the Former Officer Agreement in excess of $30 million. The exercise price of the call feature for all of the Perpetual Securities is the amount then outstanding on the 2007 Note. The Company, at its sole discretion, may elect to pay the exercise price in cash or via the extinguishment of the 2007 Note.

Note Receivable

6 Months Ended

Jun. 30, 2015

Receivables [Abstract]

Note Receivable

4.	Note Receivable

On March 30, 2007, the Company entered into the 2007 Note with the Former Officer, pursuant to which the Company loaned $4.8 million to the Former Officer. Interest accrues on the 2007 Note at a rate per annum equal to the lowest rate necessary to meet the Internal Revenue Code requirements for the applicable federal rate and is payable at maturity. Under the original terms of the 2007 Note, the entire principal balance and any accrued but unpaid interest would have become due on the earlier of (1) March 30, 2017 or (2) the date on which the Former Officer received in excess of $10 million in proceeds from the sale of any shares of capital stock of TTP, Inc., PharmaCore, Inc. or any of their subsidiaries. See Note 9 for additional discussion of PharmaCore, Inc. As of December 31, 2014, the 2007 Note had an aggregate outstanding principal amount of $4.8 million, and $1.8 million of accrued and unpaid interest. As of June 30, 2015, the 2007 Note had an aggregate outstanding principal amount of $4.8 million, and $1.9 million of accrued and unpaid interest.

On March 28, 2014, the Company entered into the Pledge Agreement with the Former Officer. Pursuant to the Pledge Agreement, the Former Officer granted a security interest to the Company in the Pledged Units to secure the Former Officer’s obligations to the Company under the 2007 Note and under the Pledge Agreement. The Pledge Agreement also amended the maturity date of the 2007 Note to be the earlier of March 30, 2018 or the date on which the Former Officer receives in excess of $10 million in proceeds from the sale of any units of the Company, HPP, PharmaCore, Inc. or any of their subsidiaries or from the sale of any assets of any of the foregoing.

As discussed in Note 3, on December 30, 2014, the Company exchanged the Pledged Units into the Perpetual Securities. The Perpetual Securities remain subject to the Pledge Agreement, have no fixed maturity date and accrue interest at a rate per annum equal to the 2007 Note. The Perpetual Securities may be prepaid without penalty in whole or in part at any time. Prepayments shall first be applied to accrued interest and then to principal. The Perpetual Securities were initially recorded at their initial fair value of $6.6 million. The increase in the fair value of the perpetual securities during the six months ended June 30, 2015 was $115 and is reflected in other income, net in the combined consolidated statements of operations.

Debt Obligations

6 Months Ended

Jun. 30, 2015

Debt Disclosure [Abstract]

Debt Obligations

5.	Debt Obligations

In June 2008, the Company entered into a promissory note with a financial institution secured by a deed of trust on land the Company purchased in 2008. The Company borrowed $2.8 million at an interest rate of 6.5% per annum. The note principal was to be repaid in one installment on June 20, 2011, with interest payments made monthly during the term of the note. On May 9, 2011, the Company entered into a Debt Modification Agreement to amend the terms of the promissory note, whereby it extended the maturity date to May 20, 2016 and changed the annual interest rate to the Prime Rate plus 1.250%, with a maximum interest rate of 6.750% and minimum rate of 4.750%. The note is to be repaid in 60 monthly payments of principal and interest, including 59 payments of approximately $22 plus a final payment for the remaining balance of principal and interest.

On March 28, 2014, the Company and M&F TTP Holdings LLC (“M&F”) agreed to exchange all $116.2 million of outstanding principal and interest due to M&F under the Note and Equity Issuance Agreement (including amounts advanced under the initial agreement plus the 2013 Promissory Notes and amounts advanced following the December 24, 2013 amendment) for 292,722,844 Series F redeemable convertible preferred units of the Company and 155,219,376 Series B redeemable convertible preferred units of HPP. Concurrently on March 28, 2014, the Company entered into an Uncommitted Advance Agreement with M&F and the Former Officer. As of December 30, 2014, the Former Officer was no longer party to this agreement. Advances made under the Uncommitted Advance Agreement are secured by substantially all of our assets and bear interest at an annual rate of LIBOR plus 10%. Principal and interest were originally payable on demand. On May 4, 2015, M&F agreed to extend the maturity date of the Uncommitted Advance Agreement to January 15, 2016. Prepayments can be made under the Uncommitted Advance Agreement without penalty. As of June 30, 2015 and December 31, 2014, $46.6 million and $27.3 million, respectively, of principal was outstanding under the Uncommitted Advance Agreement.

Commitments and Contingencies

6 Months Ended

Jun. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

6.	Commitments and Contingencies

Legal Matters

From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount.

Columbia University Agreement

In May 2015, the Company entered into a worldwide exclusive agreement with Columbia University (“Columbia”) to license certain intellectual property from Columbia. Under the agreement, the Company is obligated to pay to Columbia (1) an annual fee of $100 from 2015 through 2021, (2) a potential regulatory milestone payment of $750 and (3) potential royalty payments at , single digit royalty rates based on net sales of licensed products as defined in the agreement.

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

Fair Value of Financial Instruments

6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

8.	Fair Value of Financial Instruments

The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, accounts payable and other accrued liabilities, approximate fair value due to their short-term nature.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The following table summarizes the conclusions reached regarding fair value measurements as of June 30, 2015:


	Balance at June 30, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
TTP Redeemable preferred securities^(a)	$	478,464	$	—	$	—	$	478,464
HPP Redeemable preferred securities^(a)		—		—		—		—
Debt^(b)		48,775		—		48,775		—
Consideration payable^(c)		4,897		—		—		4,897
Note payable^(d)		6,709		—		—		6,709
Contingent distribution^(a)		27,054		—		—		27,054

Total	$	565,899	$	—	$	48,775	$	517,124

(a)

The equity fair value was allocated using the option pricing method (“OPM”). The value of equity was determined using a discounted cash flow (“DCF”) method and adjusted for any applicable separate components of the value such as net operating loss carryforwards, excess or deficit working capital, and fair value of debt instrument.

(b)	Debt was valued using a yield method, (an income valuation method) for debt securities and a probability-weighted framework based on the expected cash flows to the debt securities under various exit scenarios discounted by the risk-adjusted discount rates.

(c)	The net present value (“NPV”) of the consideration payable was valued using the DCF method.

(d)	The note payable was valued using a lattice model.


	Changes in Level 3 Instruments for the six months ended June 30, 2015
2015	Balance at January 1		Net change in fair value included in earnings		Net change in fair value⁽¹⁾		Purchases/ Issuance		Sales/ Repurchases		Balance at June 30
TTP Redeemable preferred units	$	412,085	$	—	$	66,379	$	—	$	—	$	478,464
HPP Redeemable preferred units		—		—		—		—		—		—
Consideration payable		4,897		—		—		—		—		4,897
Note payable		6,594		115		—		—		—		6,709
Contingent distribution		26,359		—		695		—		—		27,054

Total	$	449,935	$	115	$	67,074	$	—	$	—	$	517,124

(1)

The above represents the change in the fair value of the Company’s redeemable preferred units. See the Combined Consolidated Statements of Changes in Redeemable Convertible Units and Members’ Deficit and Note 7 for additional changes in the carrying value of the Company’s redeemable preferred units.

There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the six months ended June 30, 2015.

Significant inputs utilized in the valuation of the Company’s redeemable convertible preferred units and contingent distribution as of June 30, 2015 were as follows:


Sale Scenario:
Annual volatility	65.3	%
Annual risk-free rate	0.2	%
Cash flow distribution scenario:
Annual volatility	78.00	%
Annual risk-free rate	2.2	%

In addition to the significant inputs above, the fair values of the redeemable convertible preferred units and the contingent distribution as of June 30, 2015 were derived utilizing forecasts through 2030 as an input to a discounted cash flow model. These forecasts represent the future expected revenues and costs associated with the drug programs currently under development, adjusted for certain probabilities of successful passage through various developmental hurdles, including successful completion of pre-clinical trials and all three phases of clinical trials, as well as FDA approval of a new drug application.

Changes in the unobservable inputs noted above would impact members’ equity and net income. For the Company’s redeemable convertible preferred units, increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the members’ equity and an increase (decrease) in the annual risk free rate would increase (decrease) the members’ equity. For the Company’s contingent distribution, increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) net income and an increase (decrease) in the annual risk free rate would increase (decrease) net income.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details

Related-Party Transactions

6 Months Ended

Jun. 30, 2015

Related-Party Transactions

9.	Related-Party Transactions

PharmaCore, Inc.

Certain unit holders of the Company also control PharmaCore, Inc. (“PharmaCore”). The Company purchases chemistry and Good Manufacturing Practices manufacturing services from PharmaCore. Total purchases from PharmaCore for the six months ended June 30, 2015 and June 30, 2014 were $0.9 million and $0.8 million, respectively.

On April 17, 2007, the Company’s Board of Directors approved $2.0 million of subordinated financing to be provided to PharmaCore. Advances were made and interest accrued before the Company entered into the Subordinated Promissory Note agreement (the “Note Agreement”) with PharmaCore on June 9, 2008. The Note Agreement was amended on April 23, 2010 to provide an additional $2.9 million of subordinated financing, with the same terms as the original note. The Note Agreement has a nine-year term, a fixed interest rate of 8.25% per annum, with maturity of June 1, 2017. No payments were required through December 31, 2014 with accrued interest capitalized into the principal balance. Thereafter, interest is to be paid quarterly. As part of the agreement, the Company received a warrant, exercisable for up to ten years, to purchase 370,370 common units of PharmaCore at an exercise price of $0.54 per unit. During the six months ended June 30, 2015 and 2014, the Company recorded interest income of $0.4 million related to this financing. The total receivable balance due from PharmaCore financing, accrued interest and cash advance activities was $10.0 million and $9.6 million at June 30, 2015 and December 31, 2014, respectively.

As of June 30, 2015 and December 31, 2014, the Company recorded an allowance for uncollectible amounts related to the PharmaCore receivable of $9.2 million and $8.8 million, respectively. The changes in the allowance during the six months ended June 30, 2015 and June 30, 2014 are reflected in other income (expense) - related party on the combined consolidated statements of operations.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References+ Details

Income Taxes

6 Months Ended

Jun. 30, 2015

Income Tax Disclosure [Abstract]

Income Taxes

10.

Income Taxes

In November 2013, TTP Inc. underwent a reorganization by contributing all of its assets to TTP, in exchange for (a) assumption of all its liabilities and (b) all membership units of TTP. The membership units of TransTech Pharma, LLC, were then distributed to the shareholders of TTP Inc. to match in kind and number the shares previously held by them in TTP Inc. Following the reorganization, the Company, a limited liability company, was treated as a partnership for U.S. federal and state income tax purposes in most jurisdictions. Partnerships generally do not pay income tax, nor recognize income tax expense, but pass their taxable attributes to the partners who pay income tax at the individual partner level. Prior to the reorganization to an LLC, TTP Inc. had significant deferred tax assets largely comprised of net operating loss carryforwards and research and development credits. As a result of recurring and anticipated future operating losses, the Company recorded a full valuation allowance against the net deferred tax assets prior to the reorganization.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Net Earnings (Loss) per Unit

6 Months Ended

Jun. 30, 2015

Earnings Per Share [Abstract]

Net Earnings (Loss) per Unit

11.

Net Earnings (Loss) per Unit

Under the two-class method, for periods with net income, basic net income per common unit is computed by dividing the net income attributable to common unit holders by the weighted-average number of common units outstanding during the period. Net income attributable to common unit holders is computed by subtracting from net income the portion of current year earnings that participating securities would have been entitled to receive pursuant to their dividend rights had all of the year’s earnings been distributed. No such adjustment to earnings is made during periods with a net loss as the holders of the participating securities have no obligation to fund losses. Diluted net loss per common unit is computed under the two-class method by using the weighted-average number of common units outstanding plus, for periods with net income attributable to common unit holders, the potentially dilutive effects of unit options and warrants. In addition, the Company analyzes the potentially dilutive effect of the outstanding participating securities under the if-converted method when calculating diluted earnings per unit in which it is assumed that the outstanding participating securities convert into common units at the beginning of the period. The Company reports the more dilutive of the approaches (two-class or if-converted) as its diluted net income per unit during the period. Due to the existence of net losses for TTP and HPP for the six months ended June 30, 2015 and June 30, 2014, basic and diluted loss per unit were the same, as the effect of potentially dilutive securities would have been anti-dilutive.

Undistributed net earnings (loss) for a given period is apportioned to participating securities based on the weighted-average common membership units outstanding during the applicable period as a percentage of the total weighted-average units outstanding during the same period.

The following table summarizes the computation of basic and diluted net loss (in thousands) and net loss per unit of TTP:


	Three months ended June 30,						Six months ended June 30,
	2015			2014			2015			2014
Net TTP loss	$	(8,233	)	$	(5,518	)	$	(15,903	)	$	(16,099	)
Accretion of TTP redeemable convertible preferred units		(22,484	)		(22,651	)		(75,077	)		(117,553	)

Net loss attributable to TTP member units, basic and diluted	$	(30,717	)	$	(28,169	)	$	(90,980	)	$	(133,652	)
Net loss per TTP member unit, basic and diluted	$	(7.33	)	$	(2.12	)	$	(21.72	)	$	(10.06	)
Weighted-average TTP member units outstanding, basic and diluted		4,188,607			13,288,608			4,188,607			13,288,608

The following table summarizes the computation of basic and diluted net earnings (loss) (in thousands) and net earnings (loss) per unit of HPP:


	Three months ended June 30,						Six months ended June 30,
	2015			2014			2015			2014
Net HPP (loss)	$	(2,179	)	$	(1,886	)	$	(4,322	)	$	(6,417	)
Accretion of HPP redeemable convertible preferred units		—			—			—			(3,726	)

Net (loss) attributable to HPP member units, basic and diluted	$	(2,179	)	$	(1,886	)	$	(4,322	)	$	(10,143	)
Net (loss) per HPP member unit, basic and diluted	$	(0.42	)	$	(0.10	)	$	(0.84	)	$	(0.52	)
Weighted-average HPP member units outstanding, basic and diluted		5,148,485			19,609,698			5,148,485			19,609,698

As of June 30, 2015, June 30, 2014 and December 31, 2014, the following TTP securities, presented on a common-unit-equivalent basis, have been excluded from the calculation of weighted-average TTP common units outstanding because their effect is anti-dilutive:


	As of June 30,				As of
	2015		2014		December 31, 2014
TTP Redeemable convertible preferred units:
TTP Series A		8,571,337		8,571,337		8,571,337
TTP Series B		2,547,593		2,547,593		2,547,593
TTP Series C		27,032,037		27,032,037		27,032,037
TTP Series D		3,614,116		3,614,116		3,614,116

TTP Series E		32,789,595		32,789,595		32,789,595
TTP Series F		1,145,947,422		1,364,765,996		1,145,947,422
TTP Warrants to purchase common units		977,462		3,851,658		991,337

Total TTP common units reserved for future issuance		1,221,479,563		1,443,172,332		1,221,493,438

As of June 30, 2015 and 2014, the following HPP securities, presented on a common-unit-equivalent basis, have been excluded from the calculation of weighted-average HPP common units outstanding because their effect is anti-dilutive:


	As of June 30,				As of
	2015		2014		December 31, 2014

HPP Redeemable convertible preferred units:
HPP Series A		49,766,563		49,766,563		49,766,563
HPP Series B		594,834,833		703,615,904		594,834,833
Warrants to purchase HPP common units		903,712		1,737,954		917,587
Options to purchase HPP common units		505,837		624,687		564,937

Total HPP common units reserved for future issuance		646,010,945		755,745,108		646,010,945

- Definition

The entire disclosure for earnings per share.

+ References+ Details

Subsequent Events

6 Months Ended

Jun. 30, 2015

Subsequent Events [Abstract]

Subsequent Events

12.

Subsequent Events

Initial Public Offering (IPO)

On August 4, 2015, vTv Therapeutics Inc. consummated its IPO of 7,812,500 shares of its Class A Common Stock at a price of $15.00 per share. The IPO raised net proceeds of approximately $109.0 million after underwriting discounts and commissions but before expenses. vTv Therapeutics Inc. used the net proceeds of the IPO to acquire vTv Units of vTv Therapeutics LLC, an entity under common control with vTv Therapeutics Inc. which holds substantially all of the assets of the Company as a result of the Reorganization Transactions described below. vTv Therapeutics Inc. intends to use the net proceeds of the IPO to fund clinical development, studies, and trials for its various products and other drug candidates, for working capital and other general corporate purposes.

Reorganization Transactions

Prior to the IPO and the Reorganization Transactions described below, TransTech Pharma, LLC and High Point Pharmaceuticals, LLC were renamed vTvx Holdings I and vTvx Holdings II, respectively. In the Reorganization Transactions:

(1)

vTvx Holdings I and vTvx Holdings II contributed substantially all of their assets, including all of their personnel and operations (the ‘‘Contributed Assets’’), to a newly formed holding company, vTv Therapeutics Holdings LLC (‘‘vTv Therapeutics Holdings’’), in return for interests of vTv Therapeutics Holdings. Assets that were not contributed included restricted cash, certain receivables unrelated to the combined operations and land included in property and equipment, net, and liabilities that were not assumed included debt, a contingent distribution payable and other related party liabilities. All assets and liabilities that were not contributed or assumed remained with vTvx Holdings I and vTvx Holdings II;

(2)

vTv Therapeutics Holdings contributed the Contributed Assets to vTv Therapeutics LLC, a newly formed Delaware limited liability company and vTv Therapeutics Holdings directed that the assets be transferred directly to vTv Therapeutics LLC on behalf of vTv Therapeutics Holdings;

(3)

vTv Therapeutics Inc. (the successor reporting entity to the Company, the “Successor”) amended and restated its certificate of incorporation and bylaws to provide that it now has two classes of common stock:

(a)

Class A Common Stock, which represents economic interests and has one vote per share, and

(b)

Class B common stock, par value $0.01 per share, (“Class B Common Stock”) which represents no economic interests and has one vote per share;

(4)

vTv Therapeutics LLC amended and restated its limited liability company agreement to provide that it has two classes of membership units:

(a)

One managing member unit, which represents no economic interests and has 100% of the voting power of vTv Therapeutics LLC; and

(b)

Non-voting vTv Units, which represent economic interests.

(5)

vTv Therapeutics LLC issued the managing member unit to vTv Therapeutics Inc.;

(6)

vTv Therapeutics LLC issued 25,000,000 vTv Units to vTv Therapeutics Holdings; and

(7)

vTv Therapeutics Inc. issued 25,000,000 shares of Class B Common Stock, which represents no economic interests in the Successor but has the right to cast one vote per share, to vTv Therapeutics Holdings which correspond to each vTv Unit held by vTv Therapeutics Holdings.

Below is a summary of the principal documents entered into in connection with the Reorganization Transactions:

Exchange Agreement

Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B Common Stock) are exchangeable for (i) shares of the Class A Common Stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A Common Stock as determined pursuant to the Exchange Agreement), at our option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A Common Stock will ultimately be determined by the entire board of directors of vTv Therapeutics Inc. (the ‘‘Board of Directors’’).

Tax Receivable Agreement

The Tax Receivable Agreement among the Successor, vTv Therapeutics Holdings and M&F provides for the payment by the Successor to vTv Therapeutics Holdings (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Successor actually realizes (or, in some circumstances, the Successor is deemed to realize) as a result of (a) the exchange of Class B Common Stock, together with the corresponding number of vTv Units, for shares of the Successor’s Class A Common Stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Successor as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.

Investor Rights Agreement

The Successor entered into an investor rights agreement with vTv Therapeutics Holdings. Under the investor rights agreement, vTv Therapeutics Holdings is initially entitled to nominate a majority of the members of the Company’s Board of Directors and designate the members of the committees of the Board of Directors.

Sale of Land

On August 18, 2015, the Company sold a portion of its assets held for sale, with a carrying value of $1.3 million, and repaid debt related to the financing of these assets of $1.3 million, resulting in no gain or loss on the sale.

TTP Series G

On July 29, 2015, the Company and M&F agreed to exchange all $27.0 million of principal and interest due to M&F under the Uncommitted Advance Agreement for 27,009.5 Series G non-convertible preferred units of vTvx Holdings I (the “TTP Series G Units”) and the operating agreement of vTvx Holdings I was amended and restated to effect the foregoing. TTP Series G Units are non-redeemable and have a liquidation preference that is senior to the TTP Series Preferred. In the event of any liquidation, dissolution or winding up of TTP, the holders of the TTP Series G Units are entitled to receive, prior to the distribution to the other holders, a liquidation amount equal to the TTP Series G Liquidation Value paid per unit ($1,000).

Transactions with Former Officer and Related Entities

On August 28, 2015, the Company and vTv Therapeutics Holdings entered into a release agreement (the “Release Agreement”) with the Former Officer and Related Entities to settle certain obligations, including the obligation to pay the Contingent Distributions, under the Former Officer Agreement. Under the Release Agreement, the Company agreed to cause vTv Therapeutics Holdings to transfer 1,346,186 shares of Class B Common Stock and the same number of corresponding vTv Units to the Former Officer and Related Entities. Under the Release Agreement and the Former Officer Agreement, the 2007 Note owed by the Former Officer to the Company was also deemed discharged and canceled and the perpetual securities of vTvx Holdings I and vTvx Holdings II having principal amounts of $6,049,963 and $543,870, respectively, held by the Former Officer, were repurchased by vTvx Holdings I and vTvx Holdings II in exchange therefor. On the same date, under the Exchange Agreement, the Former Officer and Related Entities exchanged those shares of Class B Common Stock and vTv Units for 1,346,186 shares of Class A Common Stock.

Summary of Significant Accounting Policies (Policies)	6 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2015
Accounting Policies [Abstract]
Unaudited Interim Financial Information	*Unaudited Interim Financial Information* The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying balance sheet as of June 30, 2015, statements of operations for the three and six months ended June 30, 2015 and 2014 and cash flows for the six months ended June 30, 2015 and 2014 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2014 contained in the final prospectus filed by the Company with the SEC on July 31, 2015 relating to the initial public offering (the “IPO”). The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of June 30, 2015 and the results of operations for the three and six months ended June 30, 2015 and 2014 and cash flows for the six months ended June 30, 2015 and 2014. The December 31, 2014 balance sheet included herein was derived from the audited financial statements, but does not include all disclosures or notes required by GAAP for complete financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three and six months ended June 30, 2015 and 2014 are unaudited. Interim results are not necessarily indicative of results for an entire year.
Use of Estimates	*Use of Estimates* The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. On an ongoing basis, the Company evaluates its estimates, including those related to the useful lives of property and equipment, the fair value of the Company’s membership units, the fair value of redeemable preferred units, the fair value of derivative liabilities, and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
Concentration of Credit Risk	*Concentration of Credit Risk* Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balances of these cash accounts frequently exceed insured limits. The accounts receivable balance at June 30, 2015 was $0. One customer represented 100% of the revenue earned during the six months ended June 30, 2015. Two customers represented 100% of the revenue during the six months ended June 30, 2014.
Cash and Cash Equivalents	*Cash and Cash Equivalents* The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.
Restricted Cash and Cash Equivalents	*Restricted Cash and Cash Equivalents* Restricted cash and cash equivalents reflect cash and cash equivalents that are pledged as collateral required by the terms of operating leases on facilities used by HPCTC.
Accounts Receivable	*Accounts Receivable* On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables.
Property and Equipment and other Long-lived Assets	*Property and Equipment and other Long-lived Assets* The Company periodically assesses it property and equipment and other long-lived assets for impairment in accordance with the relevant accounting guidance. During 2014, the Company determined that certain of its land assets met the criteria for held-for-sale accounting treatment and, accordingly, adjusted the carrying value of such assets to the amount of the expected proceeds less costs of disposal, which was lower than the original carrying value. As of June 30, 2015 and December 31, 2014, the carrying value of assets held for sale was $2.7 million and $2.8 million, respectively.
Revenue Recognition	*Revenue Recognition* The Company uses the revenue recognition guidance established by ASC Topic 605, “Revenue Recognition.” The Company recognizes revenue when 1) persuasive evidence of an arrangement exists; 2) the service has been provided to the customer; 3) collection of the fee is reasonably assured; and 4) the amount of the fee to be paid by the customer is fixed or determinable. In determining the accounting for collaboration and alliance agreements, the Company follows the provisions of ASC Topic 605, Subtopic 25, “Multiple-Element Arrangements” (“ASC 605-25”) and ASC 808 (“Collaborative Arrangements”). ASC 605-25 provides guidance on whether an arrangement that involves multiple revenue-generating activities or deliverables should be divided into separate units of accounting for revenue recognition purposes and, if division is required, how the arrangement consideration should be allocated among the separate units of accounting. If a deliverable has value on a stand-alone basis, the Company treats the deliverable as a separate unit of accounting. If the arrangement constitutes separate units of accounting according to the separation criteria of ASC 605-25, the consideration received is allocated among the separate units of accounting and the applicable revenue recognition criteria is applied to each unit. The Company determines how to allocate amounts received under agreements among the separate units based on the respective selling price of each unit. If the arrangement constitutes a single unit of accounting, the revenue recognition policy must be determined for the entire arrangement and the consideration received is recognized over the period of inception through the date the last deliverable within the single unit of accounting is expected to be delivered. Collaboration research and development revenue is earned and recognized as research is performed and related expenses are incurred. Non-refundable upfront fees are recorded as deferred revenue and recognized into revenue as license fees and milestones from collaborations on a straight-line basis over the estimated period of the Company’s substantive performance obligations. If the Company does not have substantive performance obligations, it recognizes non-refundable upfront fees into revenue ratably over the period during which the product deliverable is provided to the customer. Revenue for non-refundable payments based on the achievement of milestone events under collaborative arrangements is recognized in accordance with ASC Topic 605, Subtopic 28, “Milestone Method” (“ASC 605-28”). Milestone events under the Company’s collaboration agreements may include research, development, regulatory, commercialization, and sales events. Under ASC 605-28, a milestone payment is recognized as revenue when the applicable event is achieved if the event meets the definition of a milestone and the milestone is determined to be substantive. ASC 605-28 defines a milestone event as an event having all of the following characteristics: (1) substantive uncertainty regarding achievement of the milestone event exists at the inception of the arrangement; (2) the event can only be achieved based, in whole or in part, on either the Company’s performance or a specific outcome resulting from the Company’s performance; and (3) if achieved, the event will result in additional payment due to the Company. The Company also treats events that can only be achieved based, in whole or in part, on either a third party’s performance or a specific outcome resulting from a third party’s performance as milestone events if the criteria of ASC 605-28 are otherwise satisfied. Research and development costs that are reimbursable under collaboration agreements are recorded in accordance with ASC Topic 605, Subtopic 45, “Principal-Agent Considerations.” Amounts reimbursed under a cost-sharing arrangement are reflected as reductions of research and development expense.
Income Taxes	*Income Taxes* The Company is treated as a partnership for income tax purposes. Accordingly, the allocated share of taxable income or loss is includable in the income tax returns of the Company’s members. The Company recognizes the effect of income tax positions only if these positions are more likely than not of being sustained. Changes in recognition or measurement are reflected in the period in which each change occurs. The Company has not recognized any uncertain tax positions and no examinations are currently being conducted by U.S., state, or local taxing authorities.
Deferred Offering Costs	*Deferred Offering Costs* Legal and accounting costs of $3.5 million, which were incurred in connection with the IPO, are reflected on the balance sheet as of June 30, 2015 as capitalized deferred offering costs. Following the consummation of the IPO (see Note 12 for more information), deferred offering costs will be offset against the proceeds of the offering and included in members’ deficit.
Segment and Geographic Information	*Segment and Geographic Information* Operating segments are defined as an enterprise’s components (business activities from which it earns revenue and incurs expenses) for which discrete financial information is (1) available; and (2) is regularly reviewed by the chief operating decision maker (CODM) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its President and Chief Executive Officer. The Company’s business operates in one reportable segment comprised of one operating segment.
Recently Issued Accounting Pronouncements Not Yet Adopted	*Recently Issued Accounting Pronouncements Not Yet Adopted* In April 2015, the FASB issued ASU No. 2015-04, “Compensation—Retirement Benefits (Topic 715): Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets,” (“ASU 2015-04”). For an entity with a fiscal year-end that does not coincide with a month-end, the amendments in this update provide a practical expedient that permits the entity to measure defined benefit plan assets and obligations using the month-end that is closest to the entity’s fiscal year-end and apply that practical expedient consistently from year to year. The practical expedient should be applied consistently to all plans if an entity has more than one plan. This ASU is effective for fiscal years beginning after December 15, 2015, with early adoption permitted. The Company does not expect ASU 2015-04 to have a material impact on its combined consolidated financial statements upon adoption. In April 2015, the FASB issued ASU No. 2015-05, “Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement,” (“ASU 2015-05”). The amendments in this update provide guidance to customers about whether a cloud computing arrangement includes a software license. If a cloud computing arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This ASU is effective for fiscal years beginning after December 15, 2015, with early adoption permitted. The Company does not expect ASU 2015-05 to have a material impact on its combined consolidated financial statements upon adoption. In April 2015, the FASB issued ASU No. 2015-06, “Earnings Per Share (Topic 260): Effects on Historical Earnings per Unit of Master Limited Partnership Dropdown Transactions (a consensus of the Emerging Issues Task Force),” (“ASU 2015-06”). The amendments in this update specify that for purposes of calculating historical earnings per unit under the two-class method, the earnings (losses) of a transferred business before the date of a dropdown transaction should be allocated entirely to the general partner. In that circumstance, the previously reported earnings per unit of the limited partners (which is typically the earnings per unit measure presented in the financial statements) would not change as a result of the dropdown transaction. Qualitative disclosures about how the rights to the earnings (losses) differ before and after the dropdown transaction occurs for purposes of computing earnings per unit under the two-class method also are required. This ASU is effective for fiscal years beginning after December 15, 2015, with early adoption permitted. The amendments in this update should be applied retrospectively for all financial statements presented. The Company does not expect ASU 2015-06 to have a material impact on its combined consolidated financial statements upon adoption. In June 2015, the FASB issued ASU No. 2015-10, “Technical Corrections and Improvements,” (“ASU 2015-10”). The amendments in this update represent changes to clarify the Codification, correct unintended application of guidance, or make minor improvements to the Codification that are not expected to have a significant effect on current accounting practice or create a significant administrative cost to most entities. The effective dates of transition guidance varies based on the amendments in this update. The amendments in this update that require transition guidance are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. All other amendments will be effective upon the issuance of this update. The Company does not expect ASU 2015-10 to have a material impact on its combined consolidated financial statements upon adoption.

Redeemable Convertible Preferred Units and Warrants (Tables)

6 Months Ended

Jun. 30, 2015

TransTech Pharma, LLC (TTP) [Member]

Schedule of Authorized, Issued and Outstanding Redeemable Convertible Preferred Units

The preferred units are carried at the greater of the original cost, liquidation preference, or fair value as indicated in the table below (in thousands except per member unit data):


	Member Units
	Authorized		Outstanding		Original Cost		Liquidation Preference		Fair Value		Carrying Value
Series A Preferred		8,571,337		8,571,337	$	2,545	$	2,545	$	3,237	$	3,237
Series B Preferred		2,547,593		2,547,593		3,500		3,500		2,897		3,500
Series C Preferred		2,343,922		2,243,922		5,514		5,514		9,328		9,328
Series D Preferred		2,442,361		2,442,361		9,556		9,556		7,707		9,556
Series E Preferred		32,789,595		32,789,595		86,700		86,700		69,923		86,700
Series F Preferred		1,367,157,023		1,145,947,422		64,476		114,595		385,372		385,372

Total		1,415,851,831		1,194,542,230	$	172,291	$	222,410	$	478,464	$	497,693

Schedule of Reserved Common Membership Units for Future Issuance

At June 30, 2015, the Company had reserved common membership units for future issuance as follows:


	TTP Common Units Reserved
Conversion of TTP Series A Preferred		8,571,337
Conversion of TTP Series B Preferred		2,547,593
Conversion of TTP Series C Preferred		27,032,037
Conversion of TTP Series D Preferred		3,614,117
Conversion of TTP Series E Preferred		32,789,595
Conversion of TTP Series F Preferred		1,145,947,422
Outstanding TTP warrants on common units		977,462

Total common units reserved for future issuance		1,221,479,563

Summary of Company's Warrant Activities During Period

TTP’s outstanding warrants and related exercise prices for the six months ended June 30, 2015 are as follows:


	Warrants			Weighted- Average Exercise Price Per Unit
Outstanding balance at January 1, 2015		991,337		$	2.94
Cancelled		(13,875	)		2.64

Outstanding balance at June 30, 2015		977,462		$	2.95

Summary of Outstanding Warrants

The following table summarizes information related to the outstanding TTP warrants as of June 30, 2015:


Exercise Price		Expiration Date	Warrants Outstanding		Warrants Exercisable
$	2.64	1/1/2016		25,000		25,000
$	2.64	11/22/2016		90,000		90,000
$	2.64	12/31/2016		24,962		24,962
$	3.00	8/27/2017		30,000		30,000
$	3.00	12/17/2017		800,000		800,000
$	3.00	1/1/2018		7,500		7,500

				977,462		977,462

High Point Pharmaceuticals, LLC (HPP) [Member]

Schedule of Authorized, Issued and Outstanding Redeemable Convertible Preferred Units

The following table summarizes authorized, issued and outstanding redeemable convertible preferred units as of June 30, 2015. The preferred units are carried at the greater of the original cost, liquidation preference, or fair value as indicated in the table below (in thousands except per member unit data):


	Member Units
	Authorized		Outstanding		Original Cost		Liquidation Preference		Fair Value		Carrying Value
Series A Preferred		49,766,563		49,766,563	$	1,194	$	1,194	$	—	$	1,194
Series B Preferred		704,118,921		594,834,833		14,276		14,276		—		14,276

Total		753,885,484		644,601,396	$	15,470	$	15,470	$	—	$	15,470

Schedule of Reserved Common Membership Units for Future Issuance

At June 30, 2015, the Company had reserved common membership units for future issuance as follows:


	HPP Common Units Reserved
Conversion of HPP Series A Preferred		49,766,563
Conversion of HPP Series B Preferred		594,834,833
Outstanding HPP warrants on common units		903,712
Options for HPP common units		505,837

Total HPP common shares reserved for future issuance		646,010,945

Summary of Company's Warrant Activities During Period

HPP’s outstanding warrants and related exercise prices for the six months ending June 30, 2015 are as follows:


	Warrants			Weighted- Average Exercise Price Per Unit
Outstanding balance at January 1, 2015		917,587		$	0.02
Cancelled		(13,875	)		0.02

Outstanding balance at June 30, 2015		903,712		$	0.02

Summary of Outstanding Warrants

The following table summarizes information about the outstanding HPP warrants as of June 30, 2015:


Exercise Price		Expiration Date	Warrants Outstanding		Warrants Exercisable
$	0.02	1/1/2016		25,000		25,000
$	0.02	11/22/2016		26,250		26,250
$	0.02	12/31/2016		24,962		24,962
$	0.02	12/17/2017		800,000		800,000
$	0.02	4/11/2018		15,000		15,000
$	0.02	5/15/2019		12,500		12,500

				903,712		903,712

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21553-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27011957&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6403732&loc=d3e21300-112643

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

+ Details

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References+ Details

- Definition

Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

Fair Value of Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2015

Fair Value Disclosures [Abstract]

Summarizes the Conclusions Reached Regarding Fair Value Measurements

The following table summarizes the conclusions reached regarding fair value measurements as of June 30, 2015:


	Balance at June 30, 2015		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
TTP Redeemable preferred securities^(a)	$	478,464	$	—	$	—	$	478,464
HPP Redeemable preferred securities^(a)		—		—		—		—
Debt^(b)		48,775		—		48,775		—
Consideration payable^(c)		4,897		—		—		4,897
Note payable^(d)		6,709		—		—		6,709
Contingent distribution^(a)		27,054		—		—		27,054

Total	$	565,899	$	—	$	48,775	$	517,124

(a)

(b)	Debt was valued using a yield method, (an income valuation method) for debt securities and a probability-weighted framework based on the expected cash flows to the debt securities under various exit scenarios discounted by the risk-adjusted discount rates.

(c)	The net present value (“NPV”) of the consideration payable was valued using the DCF method.

(d)	The note payable was valued using a lattice model.


	Changes in Level 3 Instruments for the six months ended June 30, 2015
2015	Balance at January 1		Net change in fair value included in earnings		Net change in fair value⁽¹⁾		Purchases/ Issuance		Sales/ Repurchases		Balance at June 30
TTP Redeemable preferred units	$	412,085	$	—	$	66,379	$	—	$	—	$	478,464
HPP Redeemable preferred units		—		—		—		—		—		—
Consideration payable		4,897		—		—		—		—		4,897
Note payable		6,594		115		—		—		—		6,709
Contingent distribution		26,359		—		695		—		—		27,054

Total	$	449,935	$	115	$	67,074	$	—	$	—	$	517,124

(1)

Summary of Company's Redeemable Convertible Preferred Units and Contingent Distribution

Significant inputs utilized in the valuation of the Company’s redeemable convertible preferred units and contingent distribution as of June 30, 2015 were as follows:


Sale Scenario:
Annual volatility	65.3	%
Annual risk-free rate	0.2	%
Cash flow distribution scenario:
Annual volatility	78.00	%
Annual risk-free rate	2.2	%

Net Earnings (Loss) per Unit (Tables)

6 Months Ended

Jun. 30, 2015

TransTech Pharma, LLC (TTP) [Member]

Summary of Computation of Basic and Diluted Net Earnings (Loss) and Net Earnings (Loss) per Unit

The following table summarizes the computation of basic and diluted net loss (in thousands) and net loss per unit of TTP:


	Three months ended June 30,						Six months ended June 30,
	2015			2014			2015			2014
Net TTP loss	$	(8,233	)	$	(5,518	)	$	(15,903	)	$	(16,099	)
Accretion of TTP redeemable convertible preferred units		(22,484	)		(22,651	)		(75,077	)		(117,553	)

Net loss attributable to TTP member units, basic and diluted	$	(30,717	)	$	(28,169	)	$	(90,980	)	$	(133,652	)
Net loss per TTP member unit, basic and diluted	$	(7.33	)	$	(2.12	)	$	(21.72	)	$	(10.06	)
Weighted-average TTP member units outstanding, basic and diluted		4,188,607			13,288,608			4,188,607			13,288,608

Schedule of Common Unit Equivalent Basis Excluded from Calculation of Weighted Average


	As of June 30,				As of
	2015		2014		December 31, 2014
TTP Redeemable convertible preferred units:
TTP Series A		8,571,337		8,571,337		8,571,337
TTP Series B		2,547,593		2,547,593		2,547,593
TTP Series C		27,032,037		27,032,037		27,032,037
TTP Series D		3,614,116		3,614,116		3,614,116

TTP Series E		32,789,595		32,789,595		32,789,595
TTP Series F		1,145,947,422		1,364,765,996		1,145,947,422
TTP Warrants to purchase common units		977,462		3,851,658		991,337

Total TTP common units reserved for future issuance		1,221,479,563		1,443,172,332		1,221,493,438

High Point Pharmaceuticals, LLC (HPP) [Member]

Summary of Computation of Basic and Diluted Net Earnings (Loss) and Net Earnings (Loss) per Unit

The following table summarizes the computation of basic and diluted net earnings (loss) (in thousands) and net earnings (loss) per unit of HPP:


	Three months ended June 30,						Six months ended June 30,
	2015			2014			2015			2014
Net HPP (loss)	$	(2,179	)	$	(1,886	)	$	(4,322	)	$	(6,417	)
Accretion of HPP redeemable convertible preferred units		—			—			—			(3,726	)

Net (loss) attributable to HPP member units, basic and diluted	$	(2,179	)	$	(1,886	)	$	(4,322	)	$	(10,143	)
Net (loss) per HPP member unit, basic and diluted	$	(0.42	)	$	(0.10	)	$	(0.84	)	$	(0.52	)
Weighted-average HPP member units outstanding, basic and diluted		5,148,485			19,609,698			5,148,485			19,609,698

Schedule of Common Unit Equivalent Basis Excluded from Calculation of Weighted Average


	As of June 30,				As of
	2015		2014		December 31, 2014

HPP Redeemable convertible preferred units:
HPP Series A		49,766,563		49,766,563		49,766,563
HPP Series B		594,834,833		703,615,904		594,834,833
Warrants to purchase HPP common units		903,712		1,737,954		917,587
Options to purchase HPP common units		505,837		624,687		564,937

Total HPP common units reserved for future issuance		646,010,945		755,745,108		646,010,945

Organization and Background - Additional Information (Detail) (Subsequent Event [Member], Class A Common Stock [Member], IPO [Member], USD $) In Millions, except Share data, unless otherwise specified	0 Months Ended
	Aug. 04, 2015	Aug. 04, 2015
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Net proceeds from initial public offering	$ 109.0
Number of shares issued through IPO	7,812,500
Common stock issued price per share		$ 15.00
TransTech Pharma LLC and High Point Pharmaceuticals LLC [Member] \| Successor [Member]
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Net proceeds from initial public offering	$ 109.0
Number of shares issued through IPO	7,812,500
Common stock issued price per share		$ 15.00

Stockholder's Equity - Additional Information (Detail) (Successor [Member], USD $)	6 Months Ended
	Jun. 30, 2015	Apr. 15, 2015 Subscription Agreement [Member]
Class of Stock [Line Items]
Common Stock, Shares Authorized	1,000
Common stock par value	$ 0.01
Common stock receivable	$ 1.00	$ 1.00
Common Stock, Shares, Issued	100	100
Common Stock, Shares, Outstanding	100	100
Common stock voting rights	Holders of Common Stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders

Description of Business and Basis of Presentation - Additional Information (Detail) (USD $)	0 Months Ended		3 Months Ended		6 Months Ended
	Aug. 04, 2015 Subsequent Event [Member] Class A Common Stock [Member] IPO [Member]	Aug. 04, 2015 Subsequent Event [Member] Class A Common Stock [Member] IPO [Member]	Jun. 30, 2015 High Point Pharmaceuticals, LLC (HPP) [Member]	Jun. 30, 2014 High Point Pharmaceuticals, LLC (HPP) [Member]	Jun. 30, 2015 High Point Pharmaceuticals, LLC (HPP) [Member]	Jun. 30, 2014 High Point Pharmaceuticals, LLC (HPP) [Member]	Mar. 12, 2008 High Point Pharmaceuticals, LLC (HPP) [Member]
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Number of common and preferred units as well as warrants to purchase common units							6,700,000
Revenues					$ 160,000	$ 0
Net loss			(2,179,000)	(1,886,000)	(4,322,000)	(6,417,000)
Net proceeds from initial public offering	$ 109,000,000
Number of shares issued through IPO	7,812,500
Common stock issued price per share		$ 15.00

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2015 Customer Segment	Jun. 30, 2014 Customer	Dec. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Accounts receivable	$ 0
Number of customers	1	2
Carrying value of assets held for sale	2,700,000		2,800,000
Number of reportable segments	1
IPO [Member]
Summary Of Significant Accounting Policies [Line Items]
Deferred offering costs	$ 3,500,000
Revenue [Member] \| Customer [Member]
Summary Of Significant Accounting Policies [Line Items]
Concentration risk percentage	100.00%	100.00%

Repurchase of Former Officer's Interest - Additional Information (Detail) (USD $)	6 Months Ended					6 Months Ended
	Jun. 30, 2015 Installments	Jun. 30, 2015 Maximum [Member]	Jun. 30, 2015 Former Officer [Member]	Jun. 30, 2015 Other Liabilities [Member] Former Officer and Related Entities [Member]	Dec. 30, 2014 Other Liabilities [Member] Former Officer and Related Entities [Member]	Jun. 30, 2015 TransTech Pharma, LLC (TTP) [Member]	Jun. 30, 2015 High Point Pharmaceuticals, LLC (HPP) [Member]	Dec. 30, 2014 High Point Pharmaceuticals, LLC (HPP) [Member] Employee Stock Option [Member]	Dec. 30, 2014 Common Stock [Member] TransTech Pharma, LLC (TTP) [Member]	Dec. 30, 2014 Common Stock [Member] High Point Pharmaceuticals, LLC (HPP) [Member]	Dec. 30, 2014 Outstanding Warrants on Common Units [Member] TransTech Pharma, LLC (TTP) [Member]	Dec. 30, 2014 Outstanding Warrants on Common Units [Member] High Point Pharmaceuticals, LLC (HPP) [Member]	Dec. 30, 2014 Series F Redeemable Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) [Member]	Mar. 28, 2014 Series F Redeemable Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) [Member]	Dec. 30, 2014 Series B Redeemable Convertible Preferred Units [Member] High Point Pharmaceuticals, LLC (HPP) [Member]	Mar. 28, 2014 Series B Redeemable Convertible Preferred Units [Member] High Point Pharmaceuticals, LLC (HPP) [Member]
Stock Repurchase Program [Line Items]
Convertible preferred units surrendered by former officer														18,730,276		9,363,128
Repurchase of units owned by former officer and related entities								58,750	9,100,001	14,462,213	2,776,522	750,000	218,818,574		108,781,071
Periodic cash payments to former officer and related entities, Total				$ 7,500,000
Cash payments to former officer and related entities at closing of the agreement					2,500,000
Periodic cash payments to former officer and related entities				5,000,000
Number of quarterly installments	8
Percentage of ownership interest transferred			100.00%
Contingent distributions		150,000,000
Principal amount of perpetual securities						$ 6,000,000	$ 500,000
Distribution payable payments to former officer under the reaffirmation agreement, description	This right is exercisable at the earlier to occur of (1) the maturity of the 2007 Note or (2) the date the Former Officer receives distribution payable payments under the Former Officer Agreement in excess of $30 million.

Note Receivable - Additional Information (Detail) (USD $)	6 Months Ended		6 Months Ended	12 Months Ended		6 Months Ended
	Jun. 30, 2015 Perpetual Securities [Member]	Dec. 30, 2014 Perpetual Securities [Member]	Jun. 30, 2015 Former Officer [Member] 2007 Note [Member]	Dec. 31, 2014 Former Officer [Member] 2007 Note [Member]	Mar. 30, 2007 Former Officer [Member] 2007 Note [Member]	Jun. 30, 2015 Former Officer [Member] Minimum [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Receivable due from a related party, net			$ 4,800,000	$ 4,800,000	$ 4,800,000
Maturity date of principal balance and unpaid interest			Mar. 30, 2017
Proceeds from sale of common stock to determine accrued interest and principal due						10,000,000
Accrued and unpaid interest			1,900,000	1,800,000
Initial fair value of securities recorded		6,600,000
Increase in fair value of perpetual securities	$ 115,000

Debt Obligations - Additional Information (Detail) (USD $)									0 Months Ended	6 Months Ended	0 Months Ended		0 Months Ended			0 Months Ended
	Jun. 30, 2015 TransTech Pharma, LLC (TTP) [Member]	Jun. 30, 2015 High Point Pharmaceuticals, LLC (HPP) [Member]	Jun. 30, 2015 Series F Redeemable Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) [Member]	Dec. 31, 2014 Series F Redeemable Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) [Member]	Jun. 30, 2015 Series B Redeemable Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) [Member]	Dec. 31, 2014 Series B Redeemable Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) [Member]	Jun. 30, 2015 Series B Redeemable Convertible Preferred Units [Member] High Point Pharmaceuticals, LLC (HPP) [Member]	Dec. 31, 2014 Series B Redeemable Convertible Preferred Units [Member] High Point Pharmaceuticals, LLC (HPP) [Member]	May 09, 2011 Promissory Note [Member]	Jun. 30, 2015 Promissory Note [Member] Installments	May 09, 2011 Promissory Note [Member] Prime Rate [Member]	Mar. 28, 2014 Promissory Note [Member] M&F TTP Holdings LLC [Member] Note and Equity Issuance Agreement [Member]	May 04, 2015 Promissory Note [Member] M&F TTP Holdings LLC [Member] Uncommitted Advance Agreement [Member]	Jun. 30, 2015 Promissory Note [Member] M&F TTP Holdings LLC [Member] Uncommitted Advance Agreement [Member]	Dec. 31, 2014 Promissory Note [Member] M&F TTP Holdings LLC [Member] Uncommitted Advance Agreement [Member]	Mar. 28, 2014 Promissory Note [Member] M&F TTP Holdings LLC [Member] Uncommitted Advance Agreement [Member] London Interbank Offered Rate (LIBOR) [Member]	Mar. 28, 2014 Promissory Note [Member] M&F TTP Holdings LLC [Member] Series F Redeemable Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) [Member] Note and Equity Issuance Agreement [Member]	Mar. 28, 2014 Promissory Note [Member] M&F TTP Holdings LLC [Member] Series B Redeemable Convertible Preferred Units [Member] High Point Pharmaceuticals, LLC (HPP) [Member] Note and Equity Issuance Agreement [Member]
Debt Instrument [Line Items]
Amount borrowed										$ 2,800,000
Debt instrument, interest rate										6.50%
Debt instrument, principal installment repayment date										Jun. 20, 2011
Description of payment of principal installments										The note principal was to be repaid in one installment on June 20, 2011, with interest payments made monthly during the term of the note.
Debt instrument, maturity date									May 20, 2016				Jan. 15, 2016
Debt instrument, interest rate											1.25%					10.00%
Debt instrument, minimum interest rate									4.75%
Debt instrument, maximum interest rate									6.75%
Debt instrument, repayment of principal and interest, number of installments										60
Debt instrument, repayment of principal and interest, number of equal installments										59
Debt instrument, monthly installment of principal and interest										22,000
Debt instrument, number of payment for remaining balance										1
Debt instrument periodic payment term										The note is to be repaid in 60 monthly payments of principal and interest, including 59 payments of approximately $22 plus a final payment for the remaining balance of principal and interest.
Outstanding principal and interest due												116,200,000
Redeemable convertible preferred units, issued	0	0	1,145,947,422	1,145,947,422	2,547,593	2,547,593	594,834,833	594,834,833									292,722,844	155,219,376
Debt instrument, principal amount outstanding														$ 46,600,000	$ 27,300,000

Commitments and Contingencies - Additional Information (Detail) (Columbia University [Member], USD $) In Thousands, unless otherwise specified	1 Months Ended	6 Months Ended
	May 31, 2015	Jun. 30, 2015
Columbia University [Member]
Commitments And Contingencies [Line Items]
Annual fee obligated to pay under the agreement	$ 100
Annual fee payment obligation period		From 2015 through 2021
Potential regulatory milestone payment	$ 750

Redeemable Convertible Preferred Units and Warrants - Additional Information (Detail) (USD $) In Thousands, except Share data, unless otherwise specified	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
TransTech Pharma, LLC (TTP) [Member]
Schedule Of Redeemable Convertible Preferred Stock [Line Items]
Redeemable convertible preferred units, authorized	1,415,851,831
Redeemable convertible preferred units, issued	0
Redeemable convertible preferred units, repurchased	0
Common member unit, share authorized	1,512,722,844	1,512,722,844
Common member unit, par value
Common member unit, share issued	4,188,607	4,188,607
Common member unit, share outstanding	4,188,607	4,188,607
TransTech Pharma, LLC (TTP) [Member] \| Series A Redeemable Convertible Preferred Units [Member]
Schedule Of Redeemable Convertible Preferred Stock [Line Items]
Redeemable convertible preferred units, authorized	8,571,337	8,571,337
Redeemable convertible preferred units, issued	8,571,337	8,571,337
Conversion price	$ 0.29697300
Liquidation preference per share	$ 0.29697300
TransTech Pharma, LLC (TTP) [Member] \| Series B Redeemable Convertible Preferred Units [Member]
Schedule Of Redeemable Convertible Preferred Stock [Line Items]
Redeemable convertible preferred units, authorized	2,547,593	2,547,593
Redeemable convertible preferred units, issued	2,547,593	2,547,593
Conversion price	$ 1.37385000
Liquidation preference per share	$ 1.37385000
TransTech Pharma, LLC (TTP) [Member] \| Series C Redeemable Convertible Preferred Units [Member]
Schedule Of Redeemable Convertible Preferred Stock [Line Items]
Redeemable convertible preferred units, authorized	2,343,922	2,343,922
Redeemable convertible preferred units, issued	2,243,922	2,243,922
Conversion price	$ 0.203979
Liquidation preference per share	$ 2.45729300
TransTech Pharma, LLC (TTP) [Member] \| Series C Redeemable Convertible Preferred Units [Member] \| Scenario, Previously Reported [Member]
Schedule Of Redeemable Convertible Preferred Stock [Line Items]
Conversion price	$ 2.45729300
TransTech Pharma, LLC (TTP) [Member] \| Series D Redeemable Convertible Preferred Units [Member]
Schedule Of Redeemable Convertible Preferred Stock [Line Items]
Redeemable convertible preferred units, authorized	2,442,361	2,442,361
Redeemable convertible preferred units, issued	2,442,361	2,442,361
Conversion price	$ 2.644131
Liquidation preference per share	$ 3.91268996
TransTech Pharma, LLC (TTP) [Member] \| Series D Redeemable Convertible Preferred Units [Member] \| Scenario, Previously Reported [Member]
Schedule Of Redeemable Convertible Preferred Stock [Line Items]
Conversion price	$ 3.91268996
TransTech Pharma, LLC (TTP) [Member] \| Series E Redeemable Convertible Preferred Units [Member]
Schedule Of Redeemable Convertible Preferred Stock [Line Items]
Redeemable convertible preferred units, authorized	32,789,595	32,789,595
Redeemable convertible preferred units, issued	32,789,595	32,789,595
Conversion price	$ 2.64413153
Liquidation preference per share	$ 2.64413153
TransTech Pharma, LLC (TTP) [Member] \| Series F Redeemable Convertible Preferred Units [Member]
Schedule Of Redeemable Convertible Preferred Stock [Line Items]
Redeemable convertible preferred units, authorized	1,367,157,023	1,367,157,023
Redeemable convertible preferred units, issued	1,145,947,422	1,145,947,422
Conversion price	$ 0.10000000
Liquidation preference per share	$ 0.10000000
High Point Pharmaceuticals, LLC (HPP) [Member]
Schedule Of Redeemable Convertible Preferred Stock [Line Items]
Redeemable convertible preferred units, authorized	753,885,484
Redeemable convertible preferred units, issued	0
Redeemable convertible preferred units, repurchased	0
Common member unit, share authorized	805,219,377	805,219,377
Common member unit, par value
Common member unit, share issued	5,148,485	5,148,485
Common member unit, share outstanding	5,148,485	5,148,485
Option outstanding	505,837
Strike price of options	$ 0.024
Fair value of options	$ 0
High Point Pharmaceuticals, LLC (HPP) [Member] \| Series A Redeemable Convertible Preferred Units [Member]
Schedule Of Redeemable Convertible Preferred Stock [Line Items]
Redeemable convertible preferred units, authorized	49,766,563	49,766,563
Redeemable convertible preferred units, issued	49,766,563	49,766,563
Conversion price	$ 0.024
Liquidation preference per share	$ 0.02400000
High Point Pharmaceuticals, LLC (HPP) [Member] \| Series B Redeemable Convertible Preferred Units [Member]
Schedule Of Redeemable Convertible Preferred Stock [Line Items]
Redeemable convertible preferred units, authorized	704,118,921	704,118,921
Redeemable convertible preferred units, issued	594,834,833	594,834,833
Conversion price	$ 0.024
Liquidation preference per share	$ 0.02400000

Redeemable Convertible Preferred Units and Warrants - Schedule of Authorized, Issued and Outstanding Redeemable Convertible Preferred Units - TransTech Pharma, LLC (Detail) (TransTech Pharma, LLC (TTP) [Member], USD $) In Thousands, except Share data, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Member Units, Authorized	1,415,851,831
Member Units, Outstanding	1,194,542,230
Original Cost	$ 172,291
Liquidation Preference	222,410
Fair Value	478,464
Carrying Value	497,693
Series A Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Member Units, Authorized	8,571,337	8,571,337
Member Units, Outstanding	8,571,337	8,571,337
Original Cost	2,545
Liquidation Preference	2,545	2,545
Fair Value	3,237
Carrying Value	3,237	2,847
Series B Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Member Units, Authorized	2,547,593	2,547,593
Member Units, Outstanding	2,547,593	2,547,593
Original Cost	3,500
Liquidation Preference	3,500	3,500
Fair Value	2,897
Carrying Value	3,500	3,500
Series C Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Member Units, Authorized	2,343,922	2,343,922
Member Units, Outstanding	2,243,922	2,243,922
Original Cost	5,514
Liquidation Preference	5,514	5,514
Fair Value	9,328
Carrying Value	9,328	7,781
Series D Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Member Units, Authorized	2,442,361	2,442,361
Member Units, Outstanding	2,442,361	2,442,361
Original Cost	9,556
Liquidation Preference	9,556	9,556
Fair Value	7,707
Carrying Value	9,556	9,556
Series E Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Member Units, Authorized	32,789,595	32,789,595
Member Units, Outstanding	32,789,595	32,789,595
Original Cost	86,700
Liquidation Preference	86,700	86,700
Fair Value	69,923
Carrying Value	86,700	86,700
Series F Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Member Units, Authorized	1,367,157,023	1,367,157,023
Member Units, Outstanding	1,145,947,422	1,145,947,422
Original Cost	64,476
Liquidation Preference	114,595	114,595
Fair Value	385,372
Carrying Value	$ 385,372	$ 312,232

- Definition

The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

- Definition

The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

- Definition

The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

Redeemable Convertible Preferred Units and Warrants - Schedule of Authorized, Issued and Outstanding Redeemable Convertible Preferred Units - High Point Pharmaceuticals, LLC (Detail) (High Point Pharmaceuticals, LLC (HPP) [Member], USD $) In Thousands, except Share data, unless otherwise specified	Jun. 30, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Member Units, Authorized	753,885,484
Member Units, Outstanding	644,601,396
Original Cost	$ 15,470
Liquidation Preference	15,470
Fair Value	0
Carrying Value	15,470
Series A Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Member Units, Authorized	49,766,563	49,766,563
Member Units, Outstanding	49,766,563	49,766,563
Original Cost	1,194
Liquidation Preference	1,194	1,194
Fair Value	0
Carrying Value	1,194	1,194
Series B Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Member Units, Authorized	704,118,921	704,118,921
Member Units, Outstanding	594,834,833	594,834,833
Original Cost	14,276
Liquidation Preference	14,276	14,276
Fair Value	0
Carrying Value	$ 14,276	$ 14,276

- Definition

+ References+ Details

- Definition

+ References+ Details

- Definition

+ References+ Details

Redeemable Convertible Preferred Units and Warrants - Schedule of Reserved Common Membership Units for Future Issuance - TransTech Pharma, LLC (Detail) (TransTech Pharma, LLC (TTP) [Member])	Jun. 30, 2015
Class of Stock [Line Items]
Common units reserved for future issuance	1,221,479,563
Outstanding Warrants on Common Units [Member]
Class of Stock [Line Items]
Common units reserved for future issuance	977,462
Series A Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Common units reserved for future issuance	8,571,337
Series B Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Common units reserved for future issuance	2,547,593
Series C Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Common units reserved for future issuance	27,032,037
Series D Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Common units reserved for future issuance	3,614,117
Series E Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Common units reserved for future issuance	32,789,595
Series F Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Common units reserved for future issuance	1,145,947,422

Redeemable Convertible Preferred Units and Warrants - Schedule of Reserved Common Membership Units for Future Issuance - High Point Pharmaceuticals, LLC (Detail) (High Point Pharmaceuticals, LLC (HPP) [Member])	Jun. 30, 2015
Class of Stock [Line Items]
Common units reserved for future issuance	646,010,945
Options for common units [Member]
Class of Stock [Line Items]
Common units reserved for future issuance	505,837
Outstanding Warrants on Common Units [Member]
Class of Stock [Line Items]
Common units reserved for future issuance	903,712
Series A Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Common units reserved for future issuance	49,766,563
Series B Redeemable Convertible Preferred Units [Member]
Class of Stock [Line Items]
Common units reserved for future issuance	594,834,833

Redeemable Convertible Preferred Units and Warrants - Summary of Company's Warrant Activities During Period - TransTech Pharma, LLC (Detail) (TransTech Pharma, LLC (TTP) [Member], USD $)	6 Months Ended
	Jun. 30, 2015
TransTech Pharma, LLC (TTP) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants, Beginning balance	991,337
Warrants, Cancelled	(13,875)
Warrants, Ending balance	977,462
Weighted-Average Exercise Price Per Unit, Beginning balance	$ 2.94
Weighted-Average Exercise Price Per Unit, Cancelled	$ 2.64
Weighted-Average Exercise Price Per Unit, Ending balance	$ 2.95

Redeemable Convertible Preferred Units and Warrants - Summary of Outstanding Warrants - TransTech Pharma, LLC (Detail) (TransTech Pharma, LLC (TTP) [Member], USD $)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.95	$ 2.94
Warrants Outstanding	977,462	991,337
Warrants Exercisable	977,462
Exercise Price $2.64 Warrant Expiring on 1/1/2016 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.64
Expiration Date	Jan. 01, 2016
Warrants Outstanding	25,000
Warrants Exercisable	25,000
Exercise Price $2.64 Warrant Expiring on 11/22/2016 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.64
Expiration Date	Nov. 22, 2016
Warrants Outstanding	90,000
Warrants Exercisable	90,000
Exercise Price $2.64 Warrant Expiring on 12/31/2016 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 2.64
Expiration Date	Dec. 31, 2016
Warrants Outstanding	24,962
Warrants Exercisable	24,962
Exercise Price $3.00 Warrant Expiring on 8/27/2017 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 3.00
Expiration Date	Aug. 27, 2017
Warrants Outstanding	30,000
Warrants Exercisable	30,000
Exercise Price $3.00 Warrant Expiring on 12/17/2017 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 3.00
Expiration Date	Dec. 17, 2017
Warrants Outstanding	800,000
Warrants Exercisable	800,000
Exercise Price $3.00 Warrant Expiring on 1/1/2018 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 3.00
Expiration Date	Jan. 01, 2018
Warrants Outstanding	7,500
Warrants Exercisable	7,500

Redeemable Convertible Preferred Units and Warrants - Summary of Company's Warrant Activities During Period - High Point Pharmaceuticals, LLC (Detail) (High Point Pharmaceuticals, LLC (HPP) [Member], USD $)	6 Months Ended
	Jun. 30, 2015
High Point Pharmaceuticals, LLC (HPP) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants, Beginning balance	917,587
Warrants, Cancelled	(13,875)
Warrants, Ending balance	903,712
Weighted-Average Exercise Price Per Unit, Beginning balance	$ 0.02
Weighted-Average Exercise Price Per Unit, Cancelled	$ 0.02
Weighted-Average Exercise Price Per Unit, Ending balance	$ 0.02

Redeemable Convertible Preferred Units and Warrants - Summary of Outstanding Warrants - High Point Pharmaceuticals, LLC (Detail) (High Point Pharmaceuticals, LLC (HPP) [Member], USD $)	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.02	$ 0.02
Warrants Outstanding	903,712	917,587
Warrants Exercisable	903,712
Exercise Price $0.02 Warrant Expiring on 1/1/2016 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.02
Expiration Date	Jan. 01, 2016
Warrants Outstanding	25,000
Warrants Exercisable	25,000
Exercise Price $0.02 Warrant Expiring on 11/22/2016 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.02
Expiration Date	Nov. 22, 2016
Warrants Outstanding	26,250
Warrants Exercisable	26,250
Exercise Price $0.02 Warrant Expiring on 12/31/2016 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.02
Expiration Date	Dec. 31, 2016
Warrants Outstanding	24,962
Warrants Exercisable	24,962
Exercise Price $0.02 Warrant Expiring on 12/17/2017 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.02
Expiration Date	Dec. 17, 2017
Warrants Outstanding	800,000
Warrants Exercisable	800,000
Exercise Price $0.02 Warrant Expiring on 4/11/2018 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.02
Expiration Date	Apr. 11, 2018
Warrants Outstanding	15,000
Warrants Exercisable	15,000
Exercise Price $0.02 Warrant Expiring on 5/15/2019 [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.02
Expiration Date	May 15, 2019
Warrants Outstanding	12,500
Warrants Exercisable	12,500

Fair Value of Financial Instruments - Summary of Conclusions Reached Regarding Fair Value Measurements (Detail) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2015
Significant Unobservable inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	$ 449,935
Net change in fair value included in earnings	115
Net change in fair value	67,074
Purchases/Issuance	0
Sales/Repurchases	0
Balance at June 30	517,124
TTP Redeemable Preferred Securities [Member] \| Significant Unobservable inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	412,085
Net change in fair value	66,379
Purchases/Issuance	0
Sales/Repurchases	0
Balance at June 30	478,464
HPP Redeemable Preferred Securities [Member] \| Significant Unobservable inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Purchases/Issuance	0
Sales/Repurchases	0
Convertible Payable [Member] \| Significant Unobservable inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	4,897
Purchases/Issuance	0
Sales/Repurchases	0
Balance at June 30	4,897
Notes Payable [Member] \| Significant Unobservable inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	6,594
Net change in fair value included in earnings	115
Purchases/Issuance	0
Sales/Repurchases	0
Balance at June 30	6,709
Contingent Distribution [Member] \| Significant Unobservable inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Balance at January 1	26,359
Net change in fair value	695
Purchases/Issuance	0
Sales/Repurchases	0
Balance at June 30	27,054
Fair Value, Measurements, Recurring [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Debt	48,775
Consideration payable	4,897
Note payable	6,709
Contingent distribution	27,054
Total	565,899
Fair Value, Measurements, Recurring [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Debt	48,775
Total	48,775
Fair Value, Measurements, Recurring [Member] \| Significant Unobservable inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Consideration payable	4,897
Note payable	6,709
Contingent distribution	27,054
Total	517,124
Fair Value, Measurements, Recurring [Member] \| TTP Redeemable Preferred Securities [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Redeemable preferred securities	478,464
Fair Value, Measurements, Recurring [Member] \| TTP Redeemable Preferred Securities [Member] \| Significant Unobservable inputs (Level 3) [Member]
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Redeemable preferred securities	$ 478,464

Fair Value of Financial Instruments - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair value equity transfers in and out of level 3 instruments	$ 0
Fair value equity transfers between level 1 and level 2 instruments	$ 0
Valuation of fair value of significant inputs utilized	Through 2030

Fair Value of Financial Instruments - Summary of Company's Redeemable Convertible Preferred Units and Contingent Distribution (Detail)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Annual volatility	65.30%
Annual risk-free rate	0.20%
Annual volatility	78.00%
Annual risk-free rate	2.20%

Related Party Transactions - Additional Information (Detail) (PharmaCore, Inc. [Member], USD $)	0 Months Ended	6 Months Ended		12 Months Ended
	Apr. 17, 2007	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
PharmaCore, Inc. [Member]
Related Party Transaction [Line Items]
Total purchases from related party		$ 900,000	$ 800,000
Financing to related party	2,000,000	2,900,000
Note agreement, term		9 years
Note agreement, interest rate		8.25%
Note agreement, maturity date		Jun. 01, 2017
Capitalization of accrued interest				0
Warrant exercisable term		10 years
Shares available under warrant exercised		370,370
Warrants, Exercise price per unit		$ 0.54
Interest income recorded		400,000	400,000
Total receivables balance from related party		10,000,000		9,600,000
Allowances for uncollectible amounts from related party		$ 9,200,000		$ 8,800,000

Net Earnings (Loss) per Unit - Summary of Computation of Basic and Diluted Net Loss and Net Loss per Unit - TransTech Pharma, LLC (Detail) (TransTech Pharma, LLC (TTP) [Member], USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share [Line Items]
Net TTP loss	$ (8,233)	$ (5,518)	$ (15,903)	$ (16,099)
Net loss attributable to TTP member units, basic and diluted	(30,717)	(28,169)	(90,980)	(133,652)
Net loss per TTP member unit, basic and diluted	$ (7.33)	$ (2.12)	$ (21.72)	$ (10.06)
Weighted-average TTP member units outstanding, basic and diluted	4,188,607	13,288,608	4,188,607	13,288,608
Redeemable Convertible Preferred Units [Member]
Earnings Per Share [Line Items]
Accretion of TTP redeemable convertible preferred units	$ (22,484)	$ (22,651)	$ (75,077)	$ (117,553)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

Net Earnings (Loss) per Unit - Summary of Computation of Basic and Diluted Net Earnings (Loss) and Net Earnings (Loss) per Unit - High Point Pharmaceuticals, LLC (Detail) (High Point Pharmaceuticals, LLC (HPP) [Member], USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
High Point Pharmaceuticals, LLC (HPP) [Member]
Earnings Per Share [Line Items]
Net HPP (loss)	$ (2,179)	$ (1,886)	$ (4,322)	$ (6,417)
Accretion of HPP redeemable convertible preferred units				(3,726)
Net (loss) attributable to HPP member units, basic and diluted	$ (2,179)	$ (1,886)	$ (4,322)	$ (10,143)
Net (loss) per HPP member unit, basic and diluted	$ (0.42)	$ (0.10)	$ (0.84)	$ (0.52)
Weighted-average HPP member units outstanding, basic and diluted	5,148,485	19,609,698	5,148,485	19,609,698

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

Net Earnings (Loss) per Unit - Schedule of Common Unit Equivalent Basis Excluded from Calculation of Weighted Average - TransTech Pharma, LLC (Detail) (TransTech Pharma, LLC (TTP) [Member])	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
TTP Redeemable convertible preferred units:
Common units reserved for future issuance	1,221,479,563	1,443,172,332	1,221,493,438
Series A Redeemable Convertible Preferred Units [Member]
TTP Redeemable convertible preferred units:
Common units reserved for future issuance	8,571,337	8,571,337	8,571,337
Series B Redeemable Convertible Preferred Units [Member]
TTP Redeemable convertible preferred units:
Common units reserved for future issuance	2,547,593	2,547,593	2,547,593
Series C Redeemable Convertible Preferred Units [Member]
TTP Redeemable convertible preferred units:
Common units reserved for future issuance	27,032,037	27,032,037	27,032,037
Series D Redeemable Convertible Preferred Units [Member]
TTP Redeemable convertible preferred units:
Common units reserved for future issuance	3,614,116	3,614,116	3,614,116
Series E Redeemable Convertible Preferred Units [Member]
TTP Redeemable convertible preferred units:
Common units reserved for future issuance	32,789,595	32,789,595	32,789,595
Series F Redeemable Convertible Preferred Units [Member]
TTP Redeemable convertible preferred units:
Common units reserved for future issuance	1,145,947,422	1,364,765,996	1,145,947,422
TTP Warrants to Purchase Common Units [Member]
TTP Redeemable convertible preferred units:
Common units reserved for future issuance	977,462	3,851,658	991,337

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

Net Earnings (Loss) per Unit - Schedule of Common Unit Equivalent Basis Excluded from Calculation of Weighted Average - High Point Pharmaceuticals, LLC (Detail) (High Point Pharmaceuticals, LLC (HPP) [Member])	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
HPP Redeemable convertible preferred units:
Common units reserved for future issuance	646,010,945	755,745,108	646,010,945
Series A Redeemable Convertible Preferred Units [Member]
HPP Redeemable convertible preferred units:
Common units reserved for future issuance	49,766,563	49,766,563	49,766,563
Series B Redeemable Convertible Preferred Units [Member]
HPP Redeemable convertible preferred units:
Common units reserved for future issuance	594,834,833	703,615,904	594,834,833
Warrants to Purchase HPP Common Units [Member]
HPP Redeemable convertible preferred units:
Common units reserved for future issuance	903,712	1,737,954	917,587
Options to Purchase HPP Common Units [Member]
HPP Redeemable convertible preferred units:
Common units reserved for future issuance	505,837	624,687	564,937

- Definition

+ References+ Details

Subsequent Events - Additional Information (Detail) (USD $)	0 Months Ended	6 Months Ended				0 Months Ended					0 Months Ended			0 Months Ended		0 Months Ended
	Aug. 04, 2015	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2015 TransTech Pharma, LLC (TTP) [Member]	Dec. 31, 2014 TransTech Pharma, LLC (TTP) [Member]	Aug. 18, 2015 Subsequent Event [Member]	Aug. 04, 2015 Subsequent Event [Member]	Aug. 18, 2015 Subsequent Event [Member]	Aug. 28, 2015 Subsequent Event [Member] 2007 Note and Perpetual Securities [Member] vTvx Holdings I [Member]	Aug. 28, 2015 Subsequent Event [Member] 2007 Note and Perpetual Securities [Member] vTvx Holdings II [Member]	Aug. 28, 2015 Subsequent Event [Member] Class A Common Stock [Member]	Aug. 04, 2015 Subsequent Event [Member] Class A Common Stock [Member] Vote	Aug. 04, 2015 Subsequent Event [Member] Class A Common Stock [Member] vTv Therapeutics Llc Units [Member]	Aug. 04, 2015 Subsequent Event [Member] Class A Common Stock [Member] IPO [Member]	Aug. 04, 2015 Subsequent Event [Member] Class A Common Stock [Member] IPO [Member]	Aug. 04, 2015 Subsequent Event [Member] Class B Common Stock [Member] Vote	Aug. 28, 2015 Subsequent Event [Member] Class B Common Stock [Member]	Aug. 04, 2015 Subsequent Event [Member] Class B Common Stock [Member]	Aug. 04, 2015 Subsequent Event [Member] Class B Common Stock [Member] vTv Therapeutics Llc Units [Member]	Jul. 29, 2015 Subsequent Event [Member] Series G Non-Convertible Preferred Units [Member] TransTech Pharma, LLC (TTP) [Member]	Jul. 29, 2015 Subsequent Event [Member] Series G Non-Convertible Preferred Units [Member] Uncommitted Advance Agreement [Member] TransTech Pharma, LLC (TTP) [Member]	Aug. 28, 2015 Subsequent Event [Member] vTv Units [Member]
Subsequent Event [Line Items]
Net proceeds from initial public offering														$ 109,000,000
Number of shares issued through IPO														7,812,500
Common stock issued price per share															$ 15.00
Common stock votes per share												1				1
Common stock par value																		$ 0.01
Voting power percentage of one managing member unit							100.00%
Amended and restated limited liability company agreement	One managing member unit, which represents no economic interests and has 100% of the voting power of vTv Therapeutics LLC	Non-voting vTv Units, which represent economic interests
Common member unit, share issued				4,188,607	4,188,607								25,000,000						25,000,000
Amount of cash savings percentage							85.00%
Description of tax receivable agreement		The Tax Receivable Agreement between the Successor and vTv Therapeutics Holdings provides for the payment by the Successor to vTv Therapeutics Holdings (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Successor actually realizes (or, in some circumstances, the Successor is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Successor’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Successor as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
Carrying value of assets held for sale		2,700,000	2,800,000					1,300,000
Repayment of debt related to financing of assets held for sale						1,300,000
Outstanding principal and interest due																					27,000,000
Non-convertible preferred units issued																					27,009.5
Non-convertible preferred units issued, aggregate liquidation preference																				$ 1,000,000
Number of shares transferred																	1,346,186					1,346,186
Principal amount of notes and securities repurchased									$ 6,049,963	$ 543,870
Number of shares of Class B common stock exchanged for shares of Class A common stock											1,346,186